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Several studies have shown epidemiologic, clinical, immune-histochemical and 
molecular differences among esophageal adenocarcinomas (EAC). Since pathogenesis 
and biology of this tumor are far to be well defined, our study aimed to examine intra- 
and inter-tumor heterogeneity and to solve crucial controversies through different 
molecular approaches. 
Results 
Target sequencing was performed for sorted cancer subpopulations from formalin 
embedded material obtained from 38 EACs, not treated with neoadjuvant therapy.  
35 out 38 cases carried at least one somatic mutation, not present in the corresponding 
sorted stromal cells. 73.7% of cases carried mutations in TP53 and 10.5% in CDKN2A. 
Mutations in other genes occurred at lower frequency, including HNF1A, not previously 
associated with EAC. Sorting allowed us to isolate clones with different mutational 
loads and/or additional copy number amplifications, confirming the high intra-tumor 
heterogeneity of these cancers. In our cohort TP53 gene abnormalities correlated with a 
better survival (P = 0.028); conversely, loss of SMAD4 protein expression was 
associated with a higher recurrence rate (P = 0.015).  
Shifting the focus on the epigenetic characterization of EAC, miR-221 and miR-483-3p 
resulted upregulated from the MicroRNA Array card analysis and confirmed with 
further testing. The up-regulation of both miRNAs correlated with clinical outcomes, in 
particular with a reduced cancer-specific survival (miR483-3p P=0.0293; miR221 
P=0.0059). In vitro analyses demonstrated an increase for miR-483-3p (fold-
change=2.7) that appear to be inversely correlated with SMAD4 expression in FLO-1 
cell-line.  
Conclusions 
In conclusion, selective sorting allowed to define the real mutation status and to isolate 
different cancer subclones.  
MiRNA expression analysis revealed a significant up-regulation of miR-221 and miR-
483-3p, which correlated with worst prognosis, implying that they can be considered 
oncogenic factors in EAC. 
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Therefore, cell sorting technologies, coupled with next generation sequencing, and the 
analysis of microRNA profiles seem to be promising strategies to guide treatment and 
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1.1 Esophageal cancer 
Esophageal cancer is considered a severe malignancy in terms of prognosis and 
mortality rate. Despite the latest improvements in diagnostics and therapy, esophageal 
cancer is still the sixth most frequent cause of cancer-related death worldwide [1], with 
an estimated 500,000 deaths in 2018 (about 6.7 mortality rate expressed as an annual 
rate per 100,000 persons at risk). A worldwide map of esophageal cancer mortality is 
shown in Figure 1 (source http://globocan.iarc.fr/). Patients that suffer from this cancer 
have very poor prognosis, with 5-years survival rates of 15-20% [2]. This is mostly due 
to late clinical presentation with advance disease.  
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Figure1: Esophageal cancer Age-standardized mortality Rate (ASR) per 100,000 worldwide-2018 (from 
GOLOCAN. Available from http://gco.iarc.fr). 
 
 
Esophageal cancer can be classified into two major histological subtypes: Squamous 
Cell carcinoma (ESCC) and Adenocarcinoma (EAC) [3]. ESCC occurs mainly in the 
upper and middle portions of esophagus, instead, EAC develops in the lower part, in 
proximity to the gastro-esophageal junction (GEJ). This classification has been recently 
confirmed and implemented at molecular level, where extensive genomic analysis of 
ESCC and EAC patients’ tumor tissues clearly defined the two cancer subtypes as 
distinct molecular entities [4]. ESCC emerges as a disease more reminiscent of 
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squamous carcinomas of other organs than of EAC, which itself bears striking 
resemblance to chromosomally unstable (CIN) gastric cancer (Figure 2) [4].  
 
 
Figure 2: Schematic representation of the subtypes of esophageal carcinoma from the proximal esophagus 
to the distal stomach. The widths of the color bands represent the proportion of the subtypes present 
within anatomic regions. Key features of the different subtypes are indicated in associated text (adapted 
from: The Cancer Genome Atlas Research Network, 2017 [4]).  
 
 
In Western countries, the incidence of esophageal adenocarcinoma has increased over 
the past two decades, however the cause of this alarming finding is unclear [2].  
The American Joint Committee on Cancer (AJCC) TNM staging system considers EAC 
as a single entity (7th and 8th editions) [5;6], although different biological behaviors 
imply that EAC may be consistently heterogeneous. Only a deep molecular 
characterization of EAC heterogeneity can lead the way to solve the existing 
controversies on classification, prevention, early diagnostic programs and modalities of 
medical or surgical treatment of these tumors.  
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1.2 Pathogenesis of Esophageal Adenocarcinoma  
A strong epidemiological association exists between esophageal adenocarcinoma and 
esophageal reflux disease (GERD) [7]. A complication of gastroesophageal reflux is 
Barrett’s esophagus (BE), considered one of the most important risk factors for 
aggressive esophageal adenocarcinoma. Barrett’s esophagus is a premalignant condition 
characterized by the replacement of the stratified squamous epithelium of the distal 
esophagus with intestinal type columnar epithelium. Chronic reflux of gastric, duodenal 
acid and bile is the initial stimulus needed to drive the development of a columnar 
phenotype [7]. The result of this process is the appearance of intestinal-metaplasia, 
conditions that can evolve into low-grade and high-grade dysplasia, and finally to EAC. 
The risk of progression from BE to EAC is 0.12-0.7% per patient per year [8;9]. The 
incidence of high-grade dysplasia and EAC increases up to 13.4% per year when low-
grade dysplasia is present [10], and up to 25% for patients diagnosed with high-grade 
dysplasia [11]. 
  
Another risk factor for EAC is obesity, specifically in those individuals with 
predominately abdominal fat distribution. Hypertrophied adipocytes and inflammatory 
cells within fat deposits create an environment of low-grade inflammation that promotes 
tumor development through the release of adipokines and cytokines [12;13]. 
 
Cigarette smoking and alcohol consumption have been established as other two 
causative factors in EAC. Previous case-controls studies have found a strong association 
between cigarette smoking and EAC in Caucasians. There was a strong dose-response 
association; in particular a longer smoking cessation was associated with a decreased 
risk of all adenocarcinomas [14]. On the other hand, the association between alcohol 
consumption and EAC and/or BE is still unclear [15;16]. 
 
Case-control studies have found that a reduced risk of BE is associated with frequent 
intake of fruits and vegetables as well as the consumption of omega-3 fatty acids and 
fiber [17]. In a large prospective study in the USA on meat consumption and esophageal 
cancer risk, red meat intake and its cooking methods were positively associated with 
EAC [17].  
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The incidence of EAC increases with age and there is a strong male predominance, with 
up to eight men/one woman affected [18]. 
 
Genetic susceptibility to EAC has been studied for years. Familial clustering of 
Barrett’s esophagus and EAC has been observed in 7% of tumor cases [19]. Genome-
wide association studies (GWAS) have led to the identification of new genetic variants 
with a small effect that increase susceptibility to EAC development [20]. In particular, 
these studies identified several single nucleotide polymorphisms SNPs located in or 
near genes that regulate development and differentiation of the esophagus, stomach and 
intestine, such as FOXP1, BARX1, FOXF1, CRTC1, GDDF1, ABCC5 and CFTR that 
were significantly associated with a higher risk of developing Barrett’s metaplasia and 
esophageal adenocarcinoma [20;21;22].  
In EAC prevention one practical issue is how to stratify cancer risk among patients with 
BE [23]. The current clinical strategy involves regular endoscopic examinations and 
biopsy pathology. This approach is controversial due to lack of specificity of a 
pathological diagnosis of dysplasia and recent data suggest that routine endoscopic 
surveillance in BE is not effective for early EAC detection. The debate on possible 
etiologic factors is still highly relevant and it is at the core of the controversies related 
also to prevention, early diagnosis programs, modalities of surgical treatments [24;25]. 
Moreover, the relationship between gastro-esophageal reflux and EAC via the sequence 
Barret’s metaplasia, dysplasia and cancer is still highly discussed [26]. 
 
1.3 Treatment options  
The treatment of patients with esophageal cancer and in particular esophageal 
adenocarcinoma is highly complex and requires an interdisciplinary approach. Patients 
with lesions limited to the mucosa can be diagnosed and treated with endoscopic 
resection [27]. In contrast, patients with adenocarcinoma might have a survival 
advantage when they undergo more extensive surgery; transthoracic esophagectomy 
with lymphadectomy for adenocarcinoma located in the distal esophagus, whereas 
transhiatal resection for tumors located at the gastroesophageal junction or gastric cardia 
[28;29].  
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However, surgical resection alone showed poor outcomes prompting considerable 
research on multimodality treatment options in esophageal adenocarcinoma. These 
options include neoadjuvant chemotherapy or chemoradiotherapy followed by surgery 
and adjuvant chemotherapy/radiotherapy following surgery. While the role of adjuvant 
therapy is questionable with current evidence not supporting its routine use [30], 
neoadjuvant treatment is the standard of care in resectable cancer [30]. Neoadjuvant 
therapy is a favored preoperative approach in the management of esophageal cancer and 
two different strategies can be applied: neoadjuvant chemotherapy alone or a 
combination of chemotherapy with radiotherapy in the neoadjuvant setting (neoadjuvant 
chemoradiotherapy). The most common neoadjuvant chemotherapeutic combination 
used in the treatment of EAC is cisplatin and 5-fluoruracil (cisplatin/5FU). Several 
studies have evaluated the role of cisplatin/5FU treatment followed by surgery 
compared with surgery alone, showing contrasting results. The Intergroup trial [31] 
showed no improvement in long-term survival with neoadjuvant chemotherapy, in 
contrast the MRC OE02 trial [32] showed a better overall survival in neoadjuvant group 
of patients. The reason for the difference in survival outcomes between these studies is 
unclear and probably depends on different tumor molecular behaviors.  
More promising results are shown from neoadjuvant chemoradiotherapy, that however 
is considering the therapy with the higher toxicity profile [33;34;35]. The most recent 
neadjuvant chemoradiotherapy approach is the Chemoradiotherapy for Esophageal 
Cancer Followed by Surgery Study (CROSS), consisting of weekly administration of 
carboplatin and paclitaxel with concurrent radiotherapy [36]. Long-term results have 
showed a statistically significant and clinically relevant increase in survival for both 
squamous cell and adenocarcinoma subtypes, with acceptable toxicity. On the basis of 
these results, the CROSS regimen is now a standard treatment in many countries [37]. 
 
For adenocarcinomas, several targeted therapies have been approved by the USA Food 
and Drug Administration (FDA) in the last few years. In 2010, based on the results of 
the Trastuzumab for Gastric Cancer (ToGA) study [38], the humanized anti-HER2 
receptor monoclonal antibody (Trastuzumab) was approved as the first targeted therapy 
for use in human epidermal growth factor receptor 2 (HER2)-positive EAC (about 20% 
to 25% of tumors). More recently, the anti-VEGF receptor antibody Ramucirumab was 
approved in combination with paclitaxel in the second-line setting [39].  
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A novel and promising therapeutic approach for the treatment of esophageal 
adenocarcinoma is the immunotherapy. Immunotherapy aims to enhance the body’s 
natural immune response by facilitating the targeting and destruction of cancer cells. 
Cytotoxic CD8 T-cells are able to recognize and eliminate cancer cells by inducing 
apoptosis or cell lysis [40]. As cancer cells mutate, they evolve to evade the anti-tumor 
immune response by developing immunosuppressive mechanisms. One of the 
suppressive immune evasion strategies employed by tumors is by controlling known 
natural immunosuppressive signaling pathways that are normally used as checkpoints to 
regulate immune cell function and prevent damage to the host during infections [41;42]. 
One such checkpoint signaling molecule is programmed cell death protein 1 (PD-1). 
PD-1 is an immune checkpoint that, under physiological conditions, suppresses the 
function of T cells, thus preventing autoimmunity [43]. The clinical rationale for 
immune checkpoint inhibition arises from the fact that tumor cells are able to 
overexpress PD-1, in order to decrease T cell-driven anti-tumor response [43]. Recently, 
FDA evaluated the effectiveness of the anti–programmed cell death protein 1 (PD-1) 
antibody (Pembrolizumab) in the second line setting for both esophageal 
adenocarcinomas and squamous cell carcinomas [44]. However, until now, despite the 
remarkable clinical achievements, the immunotherapeutic approaches resulted to be 
beneficial only for a subset of cancer patients [45;46;47].  
 
1.4 Esophageal Adenocarcinoma: current classifications and 
prognostic factors 
 
1.4.1 Staging of EAC  
Esophageal cancer staging is defined by the American Join Committee on Cancer 
(AJCC) TNM Staging System based on the depth of invasion of the primary tumor (T), 
lymph node involvement (N) and extent of metastatic disease (M) (Figure 3). The recent 
7th and 8th editions AJCC TNM system harmonized EAC staging, and included all 
tumors in the “adenocarcinoma of the esophagus” chapter, which comprehends 
adenocarcinomas located in the distal thoracic esophagus, esophagogastric junction and 
within the first 5 cm of the stomach [5;6]. 
 




Figure 3: Adenocarcinoma stage groupings. T=primary tumor characteristics; N= regional lymph nodes 
infiltration; M=distant metastases; G= histologic grade (G1 well differentiated, G2 moderately 
differentiated, G3 Poorly differentiated, G4 undifferentiated) (adapted from: Rice TW et al., 2010 [5]). 
 
 
This approach is still controversial, since studies demonstrated differences of anatomy, 
metastatic patterns and survival depending on whether adenocarcinomas are 
predominantly esophageal or gastric in location, or according to immune-histological 
parameters [29;48].  
Therefore, in recent years, different types of EAC classifications have been developed 
in order to resolve pending controversies and to improve the diagnosis and treatment of 
patients affected by adenocarcinoma of the esophagus, therefore improving the outcome 
of the disease.  
 
1.4.2 Classification according to position: the Siewert classification 
Siewert and colleagues proposed a classification based on anatomic-topographic 
features [49]. In particular, Siewert classification differentiated three tumor entities 
within cardia area [50]:  
– EAC type I: adenocarcinoma of the distal esophagus, which usually arises from an 
area with specialized intestinal metaplasia of the esophagus, i.e. Barrett’s esophagus, 
and may infiltrate the esophago-gastric junction from above; 
 – EAC type II: true carcinoma of the cardia, arising from the cardia epithelium or short 
segments with intestinal metaplasia at the esophago-gastric junction;  
-Chapter 1 - 
 13 
– EAC type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric 
junction and distal esophagus from below. 
Siewert type II and type I carcinomas show different patterns of lymphatic 
dissemination, possibly implying different surgical strategies in regard to the resection 
area and to the level of lymphadenectomy. In particular, patients with EAC type I may 
achieve complete remission by radical transmediastinal esophagectomy and abdomino-
thoracic esophagectomy, instead in patients with EAC type II and type III an extended 
total gastrectomy and transhiatal resection of the distal esophagus have proven to be the 
best surgical option [29]. 
 
1.4.3 Different morphological and histological spectrum of esophageal 
adenocarcinoma 
Esophageal adenocarcinoma often arises as a stepwise progression of precursor lesions 
from low-grade epithelial dysplasia to high-grade dysplasia to adenocarcinoma. 
Therefore, dysplasia plays the major role in cancer development. There are two main 
types of glandular dysplasia involving the lower esophagus: adenomatous-type 
dysplasia and foveolar dysplasia. Based on characteristics of dysplastic lesions, EACs 
exhibit a wide morphological spectrum [51]. 
 
An intestinal-like morphology is characterized by the presence of pseudo-stratified 
columnar cells with hyperchromatic cigar-like shaped nuclei, generally in association 
with BE, with or without foci of adjacent adenomatous dysplasia (Figure 4A). 
 
A gastric-foveolar-like morphology is characterized by the presence of cuboidal cells 
and round-oval nuclei with prominent nucleoli, generally associated to gastric intestinal 
columnar epithelium, not necessarily related with esophageal intestinal specialized 
epithelium. Dysplastic foveolar glands are positive for MUC5AC, rarely for MUC6, and 
negative for MUC2 and CDX2. High-grade foveolar dysplasia tends to be associated 
with poorly differentiated adenocarcinoma (Figure 4B). 
 
Lastly, a cardiopyloric-like histotype, the less common type of esophageal 
adenocarcinoma, is characterized by large cells with clear cytoplasm, basal or centrally 
located nuclei, increase in nuclear/cytoplasmic ratio. Histologically, it consists of 
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packed pyloric-type tubules lined by cuboidal to low columnar cells with eosinophilic, 
ground glass cytoplasm devoid of an apical mucin cap. The glands are immunoreactive 
for MUC5AC and MUC6. These lesions more frequently exhibit high-grade 
cytoarchitectural atypia [51].  
 
The signet-ring cell carcinoma (SRCC) represents another infrequent histotype, 
characterized by large vacuoles full of mucin that displace the nucleus to the cell’s 
periphery (Figure 4C). It often occurs after the disease has advanced and consequently, 




Figure 4: Morphological classification of EAC based on hematoxylin and eosin staining (20X). A. 
intestinal-like morphology, B. gastric-foveolar-like morphology, C. signet-ring cell carcinoma.  
 
 
1.4.4 Histological classification according to Lauren 
The Lauren classification, originally designed to classify gastric cancer, is a 
histopathological classification system with prognostic value expanded to esophageal 
adenocarcinoma [53;54]. 
It divides EAC into three subtypes:  
- Intestinal type, which forms glands and resembles adenocarcinoma of the large 
intestine;  
- Diffuse type, which consists of poorly cohesive cells with little or no gland formation, 
often containing various proportions of signet ring cells;  
- Mixed type, which exhibits components of both intestinal and diffuse type carcinomas. 
The majority of tumors can be classified as intestinal or mixed types, whereas the 
incidence of the diffuse types is lower than 15% [54]. Although the EAC diffuse type is 
seen with less frequency, it is associated with a significantly worse prognosis compared 
with intestinal type tumors (Figure 5) [53].  




Figure 5: Overall survival according to the Lauren classification (adapted from: Van der Kaaij RT, et al., 
2017 [53]).  
 
 
Moreover, previous studies suggested a poorer response to neoadjuvant 
chemoradiotherapy and a higher risk of lymph node metastases in the diffuse type than 
in intestinal type carcinomas [55]. 
 
1.4.5 Immuno-histologic profiles of esophageal adenocarcinoma 
Recent studies revealed the presence of differences in the biologic behavior of EAC, 
with the identification of three distinct entities on the basis of the expression pattern of 
tumor cytokeratin 7 (CK7) and cytokeratin 20 (CK20), the presence or absence of 
Barrett’s intestinal metaplasia (BIM) and gastric intestinal metaplasia (GIM). These 
different immunoprofiles could allegedly correspond to a Barrett’s esophagus-like type 
(CK7+/CK20-), a gastric cancer–like type (CK7-/CK20+), and a third undefined or 
mixed type (CK7+/CK20+) [29]. 
As the literature documents, different patterns of metastatic spread by means of the 
lymph nodes exist in EAC. It has been demonstrated that according to the presence or 
absence of BIM and GIM in the esophagus and cardia, adenocarcinoma show different 
patterns of lymphatic metastatization, which reflect different biologic and 
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carcinogenetic pathways: the BIM+/GIM- tumors spread to the thoracic stations, 
whereas abdominal lymph nodes are metastasized by BIM-/GIM- and BIM-/GIM+ 
tumors [48]. The BIM-/GIM- group includes patients with higher stage (III-IV) tumors 
and a more aggressive disease compared to the BIM+/GIM- ones. Therefore, EACs 
cannot be always considered a unique pathological entity and a gastroesophageal reflux 
disease-related tumor; other pathogenetic pathways should be taken into consideration 
[48].  
 
1.5 Genomic characterization of EAC 
Development of massively parallel and less costly sequencing techniques (next-
generation sequencing, NGS) has improved our understanding of molecular factors 
associated with EAC development. The recent sequencing approaches including whole 
exome sequencing (WES) and whole-genome sequencing (WGS), allowed to identify 
frequent somatic structural rearrangements, copy number alterations and single-
nucleotide mutations, demonstrating a high mutational frequency and high inter-sample 
heterogeneity in EAC [56]. 
 
The evolution from Barrett’s esophagus to adenocarcinoma is underlined by continuous 
DNA damage caused by reflux and chronic inflammatory factors. In particular, previous 
studies have shown that the evolution from Barrett’s esophagus to adenocarcinoma is 
dominated by loss of TP53, genome doubling, chromosomal instability (CIN) and a 
high frequency of chromothripsis events resulting in genome diversity and increase of 
the prevalence of focal amplifications and copy number gains/losses [57]. In fact, in 
consequence of TP53 loss, whole-genome doubling occurs, which enhances tumor 
progression, requiring few other mutations [58]. These genomic catastrophes can occur 
at any stage and dramatically accelerate progression of BE to high-grade dysplasia and 
cancer (Figure 6). 
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Figure 6: Paths of BE progression to EAC. Findings from next-generation sequencing studies indicate BE 
progression can accelerate via genome doubling, genome catastrophes, and other unknown mechanisms—
even at early stages of tumor progression (adapted from: Contino G. et al., 2017 [57]). 
 
 
The histological diversity of EAC is also mirrored by the genetic diversity of these 
tumors. Large-scale sequencing studies revealed three distinct mutational signatures for 
EAC [59]: 
- enrichment for BRCA signatures with prevalent defects in the homologous 
recombination pathway;  
- dominant T>G mutational pattern associated with a high mutational load and 
neoantigen burden; 
- C>A/T mutational pattern with evidence of aging imprint.  
 
Although the considerable level of genetic heterogeneity, the TP53 gene is the most 
frequently mutated gene in EACs (80.5%), ahead of CDKN2A (30%) (TCGA, 
PanCancer Atlas, data updated to September 2019). However, the percentage of 
CDKN2A inactivation increased up to 76% of tumors when considering also epigenetic 
silencing mechanisms [60]. Therefore, the TP53-pathway is the most frequently 
mutated one in EAC. 
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Cell cycle regulation is affected not only by inactivation of TP53 and CDKN2A but also 
by amplification of the 7q21 region, which harbors the CDK6 gene that was found 
amplified in 35% of EACs [4; 61]. CDK6 is a serine/therionine kinase whose activity is 
independent on binding to D-type cyclins (CCND1, CCND2 and CCND3) and it 
phosphorylates and inhibits the pRB tumor suppressor allowing cell cycle progression 
during mitogen-dependent early G1-phase [62]. The deregulation of the cell cycle 
control pathway includes overexpression of cyclins (CCND1 and CCNE) and protein 
kinases (CDK6 and CDK4) or loss of CDK inhibitors, such as INK4A. Aberrant 
expression of these cell cycle regulators has been observed in many tumors including 
EAC as a result of chromosomal amplification [63;61]. The MYC gene, which regulates 
proliferation, is also amplified in approximately 30% EACs [64].  
 
Among frequently altered genes are receptor tyrosine kinases (RTKs) of the EGFR 
family and their downstream mediators. Amplification of the ERBB2 gene is the most 
prominent receptor alteration in EACs that was found in 32% of tumors [64].  
 
In addition to ERBB2 and EGFR gene amplifications, which can potentially activate the 
PI3K pathway, other mutations were reported in PI3KCA, PI3KR1 and PTEN [56]. 
 
NGS analyses also revealed a dysregulation of the TGFβ pathway, with its components 
frequently mutated. The more recurrently altered gene in this pathway is SMAD4 (22%) 
(TCGA, PanCancer Atlas, data updated to September 2019). 
 
EAC also shows loss-of-function mutations and copy number alterations (CNAs) in 
ARID1A, ARID2, SMARCA4, and PBRM1 genes that encode components of the 
SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin-remodeling complex. The 
SWI/SNF complex is an evolutionarily conserved multi-subunit complex involved in 
chromatin restructuring that contribute to transcriptional activation and repression. 
Alterations of the SWI/SNF complex are not unique to EAC and are found in over 20% 
of human malignancies [60]. 
 
Except TP53, relatively few genes are recurrently point-mutated, demonstrating a high 
mutational frequency and high degree of genetic heterogeneity between EAC patients. 
The highly heterogeneous landscape, often difficult to correlate with clinical outcomes, 
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explains the problems encountered to date in finding suitable avenues for tailored 
therapies [56]. 
 
1.5.1 TP53 and CDKN2A 
TP53 is a tumour-suppressor gene located on the short arm of chromosome 17. This 
gene encodes the p53 protein, which acts as a transcription factor that plays a key role in 
cell cycle regulation, DNA synthesis inhibition, damaged DNA repair and apoptosis 
[65;66]. For its functions, it can be considered a driver gene in different human types of 
cancer.  
 
TP53 is frequently inactivated by point mutations in many cancers [67]. These 
mutations are primarily missense variants that inhibit the binding of p53 protein to its 
target DNA regulatory regions, therefore blocking the p53-dependent transcription. 
TP53 missense mutations are distributed in all coding exons of the TP53 gene, with a 
strong predominance in exons 4-9, which encode the DNA-binding domain of the 
protein. About 30% of the mutations, found in many different cancers, fall within 6 
“hotspot” residues (residues R175, G245, R248, R249, R273, and R282) [68]. In 
heterozygous cancer samples, where both wild-type (wt) and mutant alleles exist, 
mutant p53 can antagonize wt p53 in a dominant negative manner [69;70]. The 
generally accepted mechanism behind this dominant negative effect is the shutdown of 
wild-type p53 function because of heteromerization with mutant p53 [69]. However, 
such a heterozygous state is often transient, as TP53 mutations are frequently followed 
by loss of heterozygosity (LOH) during cancer progression [71]. Nevertheless, 
accumulating evidence supports that a dominant negative effect can play an oncogenic 
activity by a gain of function mechanism [72].  
 
For these reasons, TP53 is intensively studied in cancer and recent analyses support the 
observation that TP53 genetic status is not a prognostic but a predictive biomarker 
influencing survival only in the presence of effective chemotherapy in colorectal cancer 
[73]. In fact, TP53 gene mutations were associated with worse survival for patients 
treated with adjuvant 5-fluorouracil (5FU) [74;75]. Indeed, patients with a normal TP53 
genetic status may experience notable benefits from neoadjuvant chemotherapy with 
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cisplatin/fluorouracil, whereas those with a mutant TP53 status appear to be at risk for 
lack of response [74;75]. 
 
Given the important role played by p53 in tumor suppression and chemotherapeutic 
drug response, a number of compounds, such as STIMA-1, PRIMA-1, MIRA-1, RITA 
and others, have been identified to restore the activity of mutant p53 [76]. PRIMA-1 
and its analog APR-246 are the more investigated compounds in this category. APR-
246 was tested in EAC cells harboring mutant p53 and found to upregulate p53 target 
genes and induce apoptosis [76]. An initial phase I clinical trial has shown APR-246 to 
be safe in humans. Phase Ib/II study (ClinicalTrials.gov Identifier: NCT02999893) 
evaluating the efficacy of APR-246 in the treatment of advanced and metastatic 
esophageal or gastro-esophageal junction cancers is currently ongoing.  
Another gene frequently mutated in EAC is CDNK2A, a p53 regulator which encodes 
two tumor suppressors with different functions: p16INK4a and p14ARF. p16INK4a is a 
specific inhibitor of the cyclin D/CDK4/6 complexes, whose inhibition leads to 
disruption of normal cell cycle and uncontrolled cell growth [77]. p14ARF interferes 
with the proper p53 response, because p14ARF is a critical upstream regulator of p53 
that activates p53 protein by blocking its Mdm2-mediated degradation [78]. Restoring 
p53 activity by inhibiting the interaction between p53 and MDM2 represents an 
attractive approach for cancer therapy. To this end, a number of small-molecule p53-
MDM2 binding inhibitors have been developed, such as Nutlin-3 [79]. 
However, Nutlin-3 treatment reduced viability and induced p53-mediated apoptosis 
only in cancer cells with wild-type p53 protein.  
 
1.5.2 TGF-b pathway – associated genes 
The transforming growth factor beta (TGF-β) pathway is implicated in regulation of cell 
growth, apoptosis, differentiation, development and inhibition of proliferation and 
inflammation in normal tissues [80;81]. However, in EAC development the TGF-β 
pathway can facilitate epithelial to mesenchymal transition (EMT), invasion, and 
metastasis [82]. TGF-β signal transducers (SMADs) are commonly lost in EACs and, 
among them, SMAD4 gene is greatly affected [56]. The product of this gene forms 
transcription complexes with other members of the SMAD protein family and regulates 
TGFβ-mediated transcription [83]. Interestingly, SMAD4 is primarily mutated in EAC, 
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but not in high grade dysplasia (HGD), providing a genetic distinction between EAC 
and HGD [84]. Loss of SMAD4 expression by immunohistochemistry was found in 
10% of EAC cases, and correlated with increased postoperative recurrence and poor 
overall survival [85]. Although mutations in SMAD4 are quite common events in 
esophageal adenocarcinoma, the principal causes of reduced SMAD4 expression are 
represented by promoter hypermethylation, promoter deletion and protein modification 
[86]. 
 
1.6 Technological advantages in the study of cancer: digital 
sorting of pure cell populations 
The development of new sequencing technologies (NGS) is arguably one of the most 
significant technological advances of the last 30 years in the field of genetics. The 
second-generation sequencing platforms have advanced rapidly to the point that several 
genomes can now be sequenced simultaneously in a single instrument run in few days 
[87]. NGS has been crucial in the identification of variants characterizing the genomic 
landscape of thousands of cancer genomes across many disease types. NGS 
technologies hold the potential to reveal the molecular underpinnings of tumor biology 
with the accuracy required for clinical implementation [88]. However, when the input 
DNA is a mixture of normal and tumor cells there is an inherent trade-off between 
sensitivity and specificity, further complicated by the fact that the tumor DNA derive 
from subpopulations with different genetic characteristics. This can dilute the signal 
associated with quantitative genomic features like copy number alterations (CNAs), loss 
of heterozygosity (LOH) and simple homozygous/heterozygous status of a variant in a 
tumor cell subpopulation. This masks variant alleles/copy number alterations to values 
close to background noise or below the detection limit and strongly impairs their 
accurate detection by NGS alone. Since these sequencing approaches have been unable 
to resolve differences in complex mixture of cells, such as heterogeneous tumors [89], 
innovative high-throughput cell sorting technologies were recently combined with NGS 
assays to isolate pure tumor cells and obtain unambiguous genetic analysis results [90]. 
In the last decade, different cell-sorting systems were developed to identify and 
recover specific individual cells of interest from complex, heterogeneous samples. 
In this thesis, we approached the study of pure cancer cells exploiting one of these 
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cell-sorting systems, named DEPArrayTM (Menarini Silicon Biosystems) [90]. 
DEPArrayTM technology is based on the ability to isolate rare single cells from low cell 
count samples, whereas, most traditional flow-cytometry instruments require several 
thousand cells to prime the system. For its characteristics, DEPArrayTM system allows to 
obtain results in a wide range of applications, including: analysis of single circulating 
tumor cells (CTCs) to characterize mutational heterogeneity, examine mechanisms of 
disease progression, monitor drug response [91] and analysis of pure tumor cells from 
FFPE samples to achieve a more accurate assessment of prevalence of various 
mutations. In the latter case, the cell sorting system can be used to separate tumor cells 
from stromal or immune cells that are present in the tissue section. A slice or a punch 
from an FFPE sample can be disaggregated to be transformed into individual cell 
suspensions and stained for DNA content and cytoskeletal markers, such as cytokeratin 
proteins (CK) and vimentin (VIM) [92]. Cytokeratin (CK) are the largest and most 
diverse class of intermediate filaments which constitutes cytoskeleton components. At 
least twenty different CKs can be expressed. They are markers of normal epithelial 
differentiation, but they can be used as diagnostic tool to detect carcinoma cells. 
Epithelial cancer cells often express CKs 8, 18 and 19 that are used in combination with 
DAPI signal to discriminate tumor cells in a heterogeneous tumor tissue [92]. However, 
besides cytokeratin, carcinoma cells sometimes express variable levels of vimentin, 
depending on the epithelial-mesenchymal transition status in cancer	 [93]. In contrast, 
mesenchymal cells, such as fibroblast, chondrocytes, macrophages, and endothelial 
cells, express only the cytoskeletal marker vimentin, a type III intermediate filament 
whose expression is abundant in tumor stroma [94]. Therefore, using these cell sorting 
capabilities, tumor cells (CK+/VIM-) can be separated from the stromal cells 














Figure7: DEPArray™ image-based sorting. A. Scatter plot of disaggregated FFPE sample showing two 
well defined populations, based on cytokeratin and vimentin markers signal: tumor (CK+/VIM-) and 
stromal (VIM+/CK-) cells. B. Histograms of integral intensity DAPI, which is proportional to the amount 
of DNA contained in the cell. Ploidy is inferred by the ratio of integral intensity DAPI of a cell population 
with reference to the integral intensity DAPI of stromal cells. C. Scatterplot of cytokeratin signal intensity 
measured against DAPI intensity. 
 
 
In this thesis, I will outline how this cell sorting technology, combined with NGS 
analysis, helped us to investigate the cancer genome complexity from FFPE esophageal 
adenocarcinoma samples.  
 
1.7 Micro-RNAs and Esophageal Adenocarcinoma  
Progression of Barrett’s esophagus toward esophageal adenocarcinoma is underlined by 
the somatically heritable deregulation of genes that can be a consequence of mutations, 
structural alterations, epigenetic events, transcriptional and post-transcriptional 
mechanisms [57]. Among these factors there are microRNAs (miRNAs), small single-
stranded noncoding RNAs of about 18–28 ribonucleotide lengths with the ability to 
regulate cell processes as differentiation, proliferation or apoptosis. They mainly act by 
targeting 3¢ untranslated region of the mRNA, resulting in either translational 
repression, mRNA degradation, or mRNA cleavage, depending on the complementarity 
between the miRNA and their target mRNA [95]. MiRNAs are generated by a 
mechanism that involves the transcription of a long precursor (pri-miRNA) and is 
operated by different groups of enzymes in the nucleus or cytoplasm. The pri-miRNA, 
located in the nucleus, is converted in pre-miRNA through the cleavage activity of the 
Drosha enzyme. The produced pre-miRNA is exported to the cytoplasm by Exportin 5. 
Upon its arrival into cytoplasm, the pre-miRNA is processed in 18-22 nucleotide 
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miRNA duplexes by the cytoplasmic RNase III Dicer. Usually, one strand of this duplex 
is degraded, whereas the other strand accumulates as a mature miRNA. In some cases, 
both strands of the duplex are viable and become functional miRNA that target different 
mRNA molecules. When two mature microRNAs originate from opposite arms of the 
same pre-miRNA and are found in similar amounts, they are denoted with a -3p or -5p 
suffix. Only one strand (mature miRNA) is stabilized and incorporated within the 
heterotrimeric complex of Argonaute-2 (Ago-2)/TAR RNA-Binding Protein 
(TRBP)/protein kinase R-activating protein (PACT) as an RNA-Induced Silencing 
Complex (RISC). The single strand miRNA incorporated acts as a template to recognize 
complementary messenger RNA (mRNA) transcript. Once found, the Argonaute-2 
protein activates and cleaves the mRNA target. This is a key process in gene silencing 
[96;97]. 
In the last decade, miRNAs have been shown to regulate several processes in normal 
physiology and miRNA dysregulation has been reported in many diseases, including 
cancer. Owing to their stable expression in serum, plasma, saliva and other body fluids, 
they can be potentially good diagnostic, prognostic and predictive biomarkers. 
Furthermore, since miRNAs act as oncogenes or tumor-suppressor genes and regulate 
individual biological pathways by regulating the number of different downstream 
molecules, they make attractive candidates as therapeutic targets. To date, several 
studies have revealed distinct miRNA expression profiles between tumor and normal or 
premalignant tissue in EAC, identifying promising miRNAs with different roles at 
multiple steps of tumor progression. In particular, Feber and colleagues [98] performed 
miRNA expression arrays on a small cohort of patients that included esophageal tissues 
from normal squamous epithelium, high-grade dysplasia, Barrett’s esophagus and EAC. 
They found miRNA profiles that were distinct for each tissue type and could distinguish 
normal from malignant tissue. Interestingly the miRNA profile of EAC was found to be 
similar to BE, reflecting the tissue specificity of miRNAs with the ability to 
discriminate between squamous and columnar tissue. Recently, numerous studies have 
identified miRNAs which are aberrantly expressed in esophageal cancer: for example, 
miR-21, -145, -192, are upregulated, whereas miRNA-31, -203, -205 and let-7 which 
are often downregulated compared to normal esophageal tissue [99]. Several studies 
have shown that aberrant expression of specific miRNAs correlated with patient 
survival in esophageal cancer, presence of metastasis and response to neoadjuvant 
therapies [100]. Although altered miRNA expression profiles are intensively studied in 
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tumors of the esophagus, many analyses focused on esophageal squamous cell 
carcinoma or only on adenocarcinoma developed from Barrett’s esophagus. To date 
there are no studies demonstrating a specific miRNA signature distinguishing different 
histological pattern of EAC (i.e. presence/absence of intestinal metaplasia or Lauren’s 
cancer subtypes). The relatively small number of EAC patients included in these studies 
also makes it difficult to obtain consistent results, and prevents the detection of any 








Understanding the molecular landscape of cancer can be challenging because of the 
genetic heterogeneity both within and between patients. Here, I reported the different 
molecular approaches used to examine tumor heterogeneity and solve crucial 
controversies on classification, staging, medical and surgical therapy of esophageal 
adenocarcinoma (EAC). 
Starting from these considerations, the aims of this thesis were: 
 
(i) to investigate intra- and inter-tumor heterogeneity in whole tumor samples and sorted 
cell populations, and correlate tumor heterogeneity/mutational profiles with clinical 
outcomes, i.e. recurrence and survival. To pursue this aim, we combined a high-
throughput cell sorting/recovery workflow with next generation sequencing (NGS) 
technologies to separate and analyze the different cancer cell populations vs normal 
(stromal) cells (Part I).  
 
(ii) to characterize the dysregulated miRNAs in EAC, compared to the non-neoplastic 
tissue counterparts, and describe the signatures of the dysregulated miRNAs in the 
different EAC histological subtypes. We correlated miRNA expression with clinical 









3.1 Genetic analysis of esophageal adenocarcinoma 
 
3.1.1 Subjects  
The first case analyzed in this study was a 53-year-old white woman who, in January 
2010 underwent subtotal esophagectomy and extended thoracic and abdominal 
lymphoadenectomy for adenocarcinoma of the esophagus, which was classified as 
Barrett’s type due to the presence of intestinal metaplasia in the esophageal mucosa and 
the absence of gastric intestinal metaplasia in the stomach. According to Lauren’s 
classification, the cancer was intestinal type, G2 T3N0M0, stage 2B (detailed clinical 
features are summarized in Table 1, Row 1, EAC1). Adjuvant chemotherapy was 
indicated because of the stage, serosa and perineural invasion (5 cycles of cisplatin). In 
the autumn of 2010, she was diagnosed with sub-centimeter right lung metastases. She 
was treated with capecitabine and trastuzumab (HER2-positive tumor cells) as a second 
line of chemotherapy, and a clear reduction in the nodules was reached. Trastuzumab 
therapy was adopted for maintenance and achieved good control of the disease until 
2014, when the progression of pulmonary metastases became evident. Because of her 
lack of tolerance to drug chemotherapy, in April and December of 2015, she underwent 
video-assisted thoracoscopic surgical (VATS) resection of two metachronous right lung 
metastatic clusters. She was treated with a combination of cancer therapies 
(Paclitaxel/Ramucirumab, Irinotecan, Capecitabine, Epirubicin) until July 2018, when 
she underwent ago-biopsy of a third pulmonary nodule that was confirmed as EAC 
metastasis. On June 2019 she was alive, again under maintenance chemotherapy, but in 
disease progression. 
Subsequently, the genetic analysis was extended to a cohort of 37 EAC patients 
submitted to primary (no neoadjuvant therapy) surgical resection (clinical features are 
summarized in Table 1). We retrospectively utilized formalin fixed paraffin embedded 
samples (FFPE) of the surgical specimens collected between 2005 and 2016. 
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Hematoxylin and eosin (HE)-stained slides from all FFPE blocks were examined to 
identify the tumor areas.  
The study received approval (# L3P1223) from the Ethical Committee “Comitato Etico 
IRST IRCCS AVR (CEIIAV)”- Italy (Reg. Sper. 109/2016 Protocol 7353/51/2016) and 
written informed consent was obtained from all patients before inclusion in the study. 
 
3.1.2 Whole-exome sequencing (WES) 
Whole Exome sequencing (WES) was performed on nine esophageal adenocarcinoma 
tissues of patients submitted to primary surgical resection and on three metachronous 
chest metastases developed in patient EAC1.  
DNA was extracted from 3 10-µm thick sections obtained from formalin-fixed paraffin-
embedded (FFPE) blocks of tumors using the QIAMP DNA Mini Kit (Qiagen, Hilden, 
Germany). Dual-index paired-end libraries followed by exome enrichment were 
prepared according to the Nextera® Rapid Capture Enrichment protocol (Illumina Inc., 
San Diego, CA, USA) using the coding exome exon kit (Nextera). 150 ng of genomic 
DNA from each tissue sample was fragmented to a size of 250-300 bp with adapter 
sequences added by tagmentation, according to the manufacturer’s instructions. 
Following purification, the tagmented DNA was amplified by PCR for 10 cycles with 
unique indices for each sample. Libraries were purified and validated for appropriate 
size on 2100 Bioanalyzer DNA 1000 chip (Agilent Technologies, Santa Clara, 
California, USA). The single DNA libraries were also quantified using Qubit dsDNA 
BR Assay Kit (ThermoFisher Scientific, Waltham, Massachusetts, USA), prior to 
normalization and pooling. Whole exome capture of 500 ng of each indexed DNA 
library was performed by pooling groups of 8 samples and hybridizing to the capture 
probes for 16 hours at 58°C. The captured regions were then bound to streptavidin 
magnetic beads, washed to remove any non-specific bound products and eluted from the 
beads. Wash and elution procedures were repeated to further enrich the targeted regions. 
The enriched library is purified again prior to quantification by Qubit dsDNA HS Assay 
kit (ThermoFisher Scientific) and the library size was checked on 2100 Bioanalyzer 
High Sensitivity DNA chip (Agilent Technologies, Santa Clara, California, USA). Each 
pool was normalized to 1.3 pM and then sequenced on an Illumina NextSeq500 
platform (Illumina) at 150 bp paired ends.  
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3.1.3 Bioinformatics data analysis  
The bioinformatics analysis of WES data began by utilizing raw reads produced by 
NextSeq500 (Illumina) sequencing platform, that were checked using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and aligned using BWA 
(bio-bwa.sourceforge.net) to the human reference (hg19). PCR-duplicated reads were 
marked and removed using Picard (http://broadinstitute.github.io/picard/). Mapping and 
coverage statistics were calculated using SAMtools (http://samtools.sourceforge.net/). 
Putative somatic variants, including SNPs and small insertions/deletions (indels), were 
identified using GATK3 software (software.broadinstitute.org/gatk/). The raw mutation 
calls were filtered to exclude false calls based on base quality and allele frequency of 
mismatch bases. The identified mutations were further annotated with Ensembl VEP 
(www.ensembl.org/Tools/VEP) and their pathogenicity was evaluated using PolyPhen2 
(genetics.bwh.harvard.edu/pph2), Provean (provean.jcvi.org), FATHMM 
(http://fathmm.biocompute.org.uk/) and MutationTaster (www.mutationtaster.org) for 
missense mutations and Human Splicing Finder (www.umd.be/HSF/) and ESEfinder 
v3.0 (krainer01.cshl.edu/cgi-bin/tools/ESE3) for putative splicing alterations. The 
identified mutations were filtered by a Minor Allele Frequency (MAF) < 0.01 and based 
on their functional impact using a customized program for prioritizing variants.  
In parallel, the copy number analyses were performed on WES data with 
EXCAVATOR2 software (sourceforge.net/projects/excavator2tool), using as control 
whole exome data derived from a pool of normal (non-tumor) samples. 
 
3.1.4 SNPhylo: phylogenetic analysis of primary tumor and metastases 
WES data were used for a phylogenetic analysis of the primary lesion and three chest 
metastases of patient EAC1. After converting the data in SNP File Format, we 
computed the phylogenetic tree with SNPhylo, using the default parameters, according 
to Lee TH et al. [101]. To calculate the phylogenetic distance, the program sums each 
branch length between two samples. Therefore, the length of a branch represents the 
estimate of evolutionary distance defined as the number of elementary substitution 
events that occurred during the time of divergence of two samples, irrespective of the 
direction of time. 
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3.1.5 LOH detection from WES data on genomic DNA 
WES data from the DNA derived from tumor samples were obtained through 
enrichment with Nextera capture kit (Illumina) and sequencing with Illumina 
NextSeq500 (Illumina), as mentioned above (paragraph 3.1.2). LoFreq software 
(csb5.github.io/lofreq/) was used to get variant calls, which were later annotated with 
Ensembl VEP (www.ensembl.org/Tools/VEP). Variant frequencies and annotations 
were used to produce a B-allele frequency plot (BAF) for investigating the presence of 
LOH regions. Given the lack of the matching normal sample and the subsequent 
inability to figure out germline heterozygous variants, only highly polymorphic sites 
(GMAF > 0.1) were used in the plot. Moreover, variant frequencies greater than 90% or 
lower than 10% were filtered out to exclude germline homozygous SNPs and 
background noise. Removal of these variants does not affect the LOH identification, 
since the expected tumor frequencies of LOH variants in unsorted samples are lower 
than 100% and greater than 0% due to contamination of normal tissue. In addition, to 
improve the interpretation of frequency trends along the genome, allele frequencies 
were smoothed using a kernel density estimation (KDE) in 20Mb overlapping bins. 
LOH regions were visually predicted focusing on stretches of consecutive variants with 
frequencies deviating from heterozygous state (~50%). 
 
3.1.6 Cell sorting protocol 
The high throughput cell sorting protocol was carried out according to the DEPArray™ 
(Menarini Silicon Biosystems) technology, based on the ability of a non-uniform 
electric field to exert forces on neutral, polarizable particles, such as cells, suspended in 
a liquid. Cells are introduced into a microfluidic chip and trapped in dynamically 
controlled dielectrophoretic (DEP) cages. Once immobilized, cells are identified using a 
combination of immunofluorescent staining and LED optical imaging. Selected cells are 
then precisely driven using DEP cage motion to a collection tube [91]. The isolation of 
carcinoma cells from FFPE archived samples, using the cytoskeletal markers, such as 
cytokeratin (CK) and vimentin (VIM) allows the recovery of the different cell 
populations [90]. Each section of 50-µm was collected in a nylon biopsy bag inside a 
50-ml conical tube, dewaxed by three sequential 10 min incubations with xylene and 
then rehydrated via decreasing ethanol washes. After washing with deionized water, the 
section was immersed in 10 mM sodium citrate buffer (pH 6.4) for 5 min at room 
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temperature and heat-treated in the same pre-warmed buffer for 1 h at 80°C. After 
cooling to room temperature, the section was washed with three sequential 5 min 
incubations with the RPMI medium (Life Technologies, Carlsbad, CA, USA). To obtain 
the cell suspension, the section was incubated in a solution of 10 ml 0.1% collagenase I-
A (Sigma-Aldrich, St. Louis, MO, USA) and 0.1% dispase (Life Technologies) at 37°C. 
The dissociation process was stopped after 45 min by placing the sample tube on ice. 
The cell suspension was resuspended by pipetting and transferred through a 30-µm 
mesh nylon filter into a 15-ml conical tube. The cell suspension was washed two times 
with ice-cold PBATw (PBS-1%BSA-0.05%Tween20 buffer) by centrifugation at 1000 
g for 5 min. The cell pellet was resuspended in 1 ml of ice-cold PBATw, and an aliquot 
of 5 × 105 cells was incubated with 100 µl of the primary monoclonal antibody mixture 
containing anti-keratin (CK) MNF116, IgG1 (DAKO, Glostrup, Denmark) (final 
concentration 3.2 µg/ml), anti-keratin (CK) AE1/AE3, IgG1 (Millipore–Chemicon, 
Burlington, Massachusetts, USA) (final concentration 10 µg/ml) and anti-vimentin 
(VIM) 3B4, IgG2a (DAKO) (final concentration = 3.1 µg/ml) in PBATw. After 30 min 
at 4°C, the cells were washed twice with ice-cold PBATw and 100 µl premixed 
secondary reagents Alexa Fluor® 488 Goat Anti-Mouse IgG1 (Life Technologies), a 
final concentration of 2.5 µg/ml for the keratin detection and Alexa Fluor® 647 Goat 
Anti-Mouse IgG2a (Life Technologies), a final concentration of 2.5 µg/ml for the 
vimentin detection, and PBATw was added to the pellet. The incubation occurred for 60 
min in the dark at 4°C and was followed by two washes with ice-cold PBATw. A DNA 
staining solution containing 10 µM DAPI (Sigma-Aldrich) in PBATw was added, and 
after an incubation of 30 min at 37°C, the cells were washed twice with PBATw with a 
5 min centrifugation at 1000 g, and the pellet was resuspended in the same buffer. 
For cell sorting on the DEPArray™, a small amount of the labeled cell suspension was 
washed twice with 1 ml of SB115 buffer (Menarini Silicon Biosystems). The pellet was 
resuspended in the same buffer and an aliquot, corresponding to approximately 24000 
cells, was loaded into the DEPArray™ A300K cartridge (Menarini Silicon Biosystems). 
Based on the fluorescent staining and the DNA content, a precise number of 
homogeneous cells in the tumor (CK+/VIM-) and stromal populations (VIM+/CK-), 
together with pools of mixed cells (unsorted), were recovered in different PCR tubes. 
The measure of DNA content is proportional to the DNA index, determined comparing 
the integral-intensity DAPI signal of tumor population with that of stromal fraction, 
used as reference. 
- Chapter 3 - 
 32 
After lysis, reagents were added to the same tubes to prepare the DEPArray™ 
OncoSeek libraries (Menarini Silicon Biosystems) or to perform Low Pass Whole 
Genome Analysis in order to detect copy number alterations (CNAs).  
 
3.1.7 Assessing FFPE DNA quality  
The DNA integrity of the cells suspension was determined using the DEPArrayTM FFPE 
QC Kit (Menarini Silicon Biosystems), before cell sorting. DNA quality assessment is 
performed by qPCR-based assay yielding a QC score defined as the ratio between the 
quantification of 132 bp amplicon and a 54 bp amplicon. This value provides a useful 
tool to evaluate the sample quality and possibly select samples with QC quality optimal 
for subsequent NGS analysis (QC ≥0.20).  
For each sample, the effectively amplifiable template (EAT), a measure of the amount 
of DNA competent for amplification, was estimated by multiplying the QC score by the 
ploidy (assessed by cell sorting) and by the number of cells recovered.  
 
3.1.8 OncoSeek genetic analysis 
Illumina-compatible, targeted NGS libraries from DEPArrayTM-sorted cell lysates were 
obtained using the DEPArrayTM OncoSeek Panel (Menarini Silicon Biosystems), 
according to the manufacture’s protocol. This panel allows the simultaneous detection 
of single nucleotide variants (SNVs), indels and copy number alterations (CNAs) from 
63 clinically-relevant oncology-related genes (Table 2). Each library was diluted 
1:10,000 and then quantified in triplicate by qPCR using the KAPA Library 
Quantification Kit (Hoffmann-La Roche, Basilea, Switzerland) following the user’s 
instructions. All libraries were pooled and NGS was performed using MiSeq v2 (150 
PE) reagents on a MiSeq instrument (Illumina) according to the manufacturer’s 
protocol. 
The FASTQ paired-end reads were trimmed using Cutadapt (cutadapt.readthedocs.io) 
according to the manufacturer’s protocol to remove synthetic primers from overlapping 
amplicons. The trimmed reads were aligned to the human reference genome (hg19) 
using the BWA software (bio-bwa.sourceforge.net). The alignment and coverage 
statistics were obtained using Samtools (samtools.sourceforge.net) and BEDTools 
(bedtools.readthedocs.io/en/latest) packages. After filtering to discard the partial, poorly 
aligned and unmapped reads, variant calls were obtained using LoFreq software 
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(csb5.github.io/lofreq). The resulting variants were annotated using Ensembl VEP 
(www.ensembl.org/Tools/VEP). The copy number alteration analysis of the OncoSeek 
data was performed using sorted populations as tests and a set of stromal cell pools from 
different samples as controls. For the copy number calling, the reads mapping to target 
amplicons of the DEPArray™ OncoSeek panel were counted. Then, the read counts 
were normalized using the following 2-step procedure: 1) between-sample 
normalization using the total number of aligned reads and 2) within-sample 
normalization using a LOWESS fitting of read counts with respect to the first 
component explaining >90% variation between regions in the control samples. The fold 
changes were computed by dividing the normalized counts in the test samples by the 
baseline and are represented by the median value of the normalized counts per amplicon 
across the control samples. The final copy number calls per gene were obtained by 
calculating the median fold changes of all gene-specific amplicons.  
 
3.1.9 Whole-Genome Low-Pass sequencing for CNA analysis 
Recovered cells were lysed using SB LysePrep™ Kit (Menarini Silicon Biosystems) 
and 46 µl of LowTE buffer (TE 0.1X) were added to the tube. The sample was then 
transferred into a microTUBE-50 AFA Fiber Screw-Cap for fragmentation by Covaris 
M220 instrument (Covaris, Woburn, Massachusetts, USA) for 3 min and 52 sec (pick 
power:50, duty factor:20, cycles/burst:200) to obtain a 150–200 bp fragment size. 
Libraries were prepared using Accel-NGS® 2S PCR-Free DNA Library kit (Swift 
Biosciences, Ann Arbor, MI, USA) according to the manufacturer’s instructions. 
20 µl of library were amplified as following: 6 µM of amplicon PCR forward primer (5′-
AATGATACGGCGACCACCGAGATC-3′), 6 µM of amplicon PCR reverse primer 
(5′-CAAGCAGAAGACGGCATACGA-3′) and 2× KAPA HiFi HotStart Ready Mix 
(Hoffman-La Roche). The PCR cycling conditions were 98 °C initial denaturation for 
45 sec, followed by 16 cycles and 15 cycles for ~100 cells and ~300 cells, respectively 
at 98 °C for 15 s, 60 °C for 30 s, and 72 °C for 1 min, and a final extension at 72 °C for 
1 min. The products were cleaned up with 0.75X Agencourt AMPure XP beads 
(Beckman Coulter Genomics, Chaska, USA) according to the manufacturer’s protocol 
and eluted in 20 µl Low TE (Swift Biosciences). 
Libraries were normalized and pooled to 4 nM based on qPCR quantification. Pooled 
samples were denatured and diluted to a final concentration of 12 pM. All samples were 
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multiplexed and sequenced in a single lane on the MiSeq using 2 × 100 bp paired-end 
sequencing with the MiSeq Reagent Kit V3 (Illumina). 
The BWA algorithm was used to align the reads to the hg19 human reference genome. 
PCR duplicates and secondary alignments were filtered out using Picard 
MarkDuplicates (http://broadinstitute.github.io/picard/) and Samtools 
(samtools.sourceforge.net). Control-FREEC algorithm was used to obtain copy-number 
calls, using the mode without control sample independently for all libraries. Read 
counts were corrected by GC content and mappability (uniqMatch option). Main ploidy 
level was estimated for each library based on best fitting of profiles to underlying copy 
number levels. 
 
3.1.10 TA-cloning for SMARCA4 PCR product 
40 ng of genomic DNA from the third metastasis biopsy of patient EAC1 was subjected 
to PCR amplification of SMARCA4 gene (exon 32), using KAPA Taq HotStart PCR Kit 
(Hoffman-La Roche) in a final volume of 50 µl, according to the manufacturer’s 
protocol. The primer sequences of exon 32 are reported in Table 3. The 213 bp 
amplicon was purified with Millipore PCR clean-up plates (Millipore–Chemicon) and 
cloned using the pCR 2.1 TA Cloning Kit (Invitrogen- Life Technologies), according to 
standard procedure. The purified amplicon was combined with 2 µl of pCR®2.1 vector 
(25 ng/µl), 1 µl of 10X Ligation Buffer, 1 µl of T4 DNA Ligase (5 units) and water for a 
final volume of 10 µl. The ligation reaction was then incubated 16 hours at room-
temperature. The ligation reaction was then gently pipetted into 50 µl of One Shot® 
TOP10 Chemically Competent E. coli (Invitrogen- Life Technologies) competent cells 
and incubated on ice for 30 min. The reaction was then incubated, without mixing or 
shaking, for exactly 30 seconds at 42°C (heat shock step). The transformed mixture was 
immediately placed again on ice for 3 min. Next, 250 µl of pre-warmed S.O.C. medium 
was added to each reaction tube and the mixture was incubated at 37°C for 1 hour at 
200 rpm in a shaking incubator. The content of each transformation vial was placed on 
an ampicillin (50 µg/ml)-LB agar plate. After an incubation of 16 hours at 37°C, the 
clones were picked up and grown in ampicillin (50 µg/ml )-LB broth at 37°C for 16 
hours. The plasmid DNA of the single collected colonies was extracted with Plasmid 
Mini Kit (Qiagen), according to the manufacturer's instruction and directly sequenced 
on both strands with primers specific for pCR®2.1 vector, forward M13 and reverse 
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M13 (Table 3). The purified sequencing products were analyzed on 3730 DNA 
Analyzer (ThermoFisher Scientific, Waltham, Massachusetts, USA). 
 
3.1.11 Sanger sequencing 
The genomic DNA was extracted from different FFPE tissue sections of the same tumor 
tissue block with QIAamp DNA Mini Kit (Qiagen). KAPAHiFi HotStart (Hoffman-La 
Roche) was used for genomic DNA amplification, according to the manufacturer’s 
protocol. The TP53 PCR products (the specific primer sequences of TP53 exons are 
reported in Table 3) and the plasmid templates (according to paragraph 3.1.9) were 
directly sequenced on both strands using the BigDye v1.1 kit (ThermoFisher Scientific) 
on 3730 DNA Analyzer (ThermoFisher Scientific). Each sequencing reaction was 
performed in a final volume of 10 µl, using 2 µl of 5X Sequencing Buffer, 0.5 µl of Big 
Dye™ Terminator v1.1 Ready Reaction mix, 1 µl of specific 10 µM primer (forward or 
reverse), 1 µl of DNA template (purified PCR products or plasmid DNA) and 5.5 µl of 
water. The reaction was conducted in the 2720 Thermal Cycler (ThermoFisher 
Scientific) setting the following program: 1 min at 96°C; 10 sec at 96°C, 4 min at 60°C 
for 35 cycles. Electropherograms were visualized with Chromas version 2.0 (Chromas, 
Technelysium, South Brisbane, Australia) and Sequencer version 4.7 (Gene Codes 
Corporation, Ann Arbor, MI, USA). 
 
3.1.12 Droplet digital PCR (ddPCR) 
The ddPCR experiments were performed for TP53_R273H (dHsaMDV2010109) and 
CDKN2A_R58* (dHsaMDS2512016) assays using the QX100/QX200 Droplet Digital 
PCR (ddPCR) system (Bio-Rad, Hercules, California, USA). The ddPCR reaction 
mixture consisted of 10 µl of a 2X ddPCR Supermix for Probes no dUTP (Bio-Rad), 1 
µl of 20X primer/probe mix and 50 ng of sample DNA from unsorted tissue material in 
a final volume of 20 µl. Mutant target and wild-type assays are provided together in a 
single tube, with FAM targeting the mutant allele and HEX targeting the wild-type 
allele. The entire reaction mixture was loaded into the sample well of a DG8 cartridge 
(Bio-Rad) together with 70 µl of droplet generation oil (Bio-Rad) and placed in the 
droplet generator (Bio-Rad). After processing, the droplets generated from each sample 
were transferred to a 96-well plate that was heat-sealed with a foil seal and then placed 
on a conventional thermal cycler. Thermal cycling consisted of a 10 min activation 
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period at 95°C followed by 40 cycles of a two-step thermal profile of 30 sec at 94°C 
denaturation and 1 min at 55°C for combined annealing-extension and 1 cycle of 98°C 
for 10 min. The ramp rate for each step was set to 2°C/sec. Droplets were read using a 
QX100/QX200 Droplet Reader (Bio-Rad), and the data were analyzed using QuantaSoft 
software (Bio-Rad). No-template controls were performed using water in place of 
template in every experiment; in all cases no amplification occurred. 
 
3.1.13 In Situ Hybridization (ISH) 
In Situ Hybridization was performed using the dual-color silver/chromogenic in situ 
hybridization (SISH) test for Her-2 gene and chromosome 17 (centromeric probe). 
Copy number alterations were identified by INFORM HER2 Dual ISH DNA Probe 
Cocktail on a Benckmark Ultra instrument (Ventana Medical Systems, Mannheim, 
Germany). Forty non-overlapping nuclei were counted at 600X microscope 
magnification.  
 
3.1.14 Immunohistochemistry (IHC) 
Immunohistochemistry was performed automatically with Benchmark XT® 
immunostainer (Ventana Medical Systems) for p53 and HER2 antigens. The 
immunohistochemical analysis was validated through positive controls (as an external 
positive control put on the slide) and negative control (by omitting the primary 
antibody). The immunoreactivity for the HER2 protein was scored according to 
American Society of Clinical Oncology/College of American Pathologists 
(ASCO/CAP) guidelines. [102]. The expression of p53 protein was defined as hyper-
expressed if there was evidence of strong and diffuse nuclear immunoreactivity [76]. 
IHC for SMAD4 was performed manually on FFPE blocks with anti-SMAD4 mouse 
monoclonal antibody (clone B-8; 200 µg/ml, diluted 1/200; Santa Cruz Biotechnology, 
Dallas, Texas, USA). In brief, deparaffinized sections were immersed in 3% H2O2 for 
10 min to abolish endogenous peroxidase activity and washed in 0.05 M TBS (pH 7.3) 
for 15 min. Antigen retrieval was performed in citrate buffer (pH 6.0) in a microwave 
oven with one cycle at 900 W for 3 min followed by a second cycle at 360 W for 13 
min. Sections were then incubated with anti-SMAD4 antibody for 1 hour at room 
temperature. The slides were subsequently rinsed three times in TBS and incubated for 
20 min with Multilink Biotinylated anti-Ig (Biogenex, Fremont, CA, USA) diluted 1:20, 
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followed by 3 min incubation with 0.05% 3-3 ¢-diaminobenzidine-tetrahydrochloride in 
0.02% H2O2. Sections were finally counterstained with Mayer's hematoxylin, dehy-
drated and mounted. The immunohistochemical analysis was validated using both 
positive controls (non-neoplastic mucosa and lymphoid cells) and negative internal 
controls (i.e. smooth muscle cells). The expression of the SMAD4 protein was defined 
by a complete loss of expression in at least 30% of cancer cells, using the same cut-off 
score identified for colon cancer in a previously published work [103;104]. 
 
3.1.15 Statistical analysis  
Data were represented as the median and interquartile range (IQR) for continuous 
variables and as n (%) for categorical variables unless otherwise stated. 
The Mann-Whitney test and one-way analysis of variance (ANOVA) were used to 
analyze continuous variables. P-values < 0.05 were considered significant. Data were 
analyzed using SPSS (version 15.0; SPSS Inc., Chicago, IL, USA).  
The statistical significance of the fold-change difference among the primary tumor and 
metastases was determined using one-way analysis of variance (ANOVA) with a 
significance level of 5%.  
Spearman’s rank correlation was used to assess the correlation between quality of 
starting DNA and performance of WES analysis. 
The cancer-specific survival was assessed using the Kaplan-Meier method and Long-
Rank test. The comparison between the histological subtypes defined according to 
Lauren’s classification and distribution of TP53 mutations was performed with the chi-
squared test for given probabilities (R software package; R Project for Statistical 
Computing, Vienna, Austria), Bonferroni's correction was applied and P-values < 0.025 
were considered significant. Multivariate analysis applying forward stepwise approach 
was used to assess the joint effect upon survival of more variables, such as age, sex, 
cancer stage, Lauren classification, presence/absence of intestinal metaplasia and TP53 
mutational status.  





3.2 MicroRNA expression profiles in esophageal 
adenocarcinoma 
 
3.2.1 Subjects  
We evaluated 112 esophageal adenocarcinoma patients, surgically treated between 2005 
and 2017 in four European Centers: Maria Cecilia Hospital, Cotignola, Italy (47 cases); 
IRCCS Policlinico San Martino, Genova, Italy (8 cases); Helsinki University Central 
Hospital, Helsinki, Finland (10 cases) and The Academic Medical Center Hospital, 
Amsterdam, Netherlands (47 cases). The inclusion and the exclusion criteria consist of 
the presence of adenocarcinoma in the esophagogastric junction in absence of 
neoadjuvant treatment (chemioradiotherapy-naïve EACs). After formalin fixation, 
surgical resections were processed and paraffin embedded (FFPE). All cases were 
examined by gastrointestinal pathologist and were classified according to morphology 
in glandular intestinal types (intestinal-like morphology), glandular non-intestinal types 
(gastric-like morphology) and signet-ring. Samples were distinguished according to 
Lauren’s and BIM/GIM classifications (detailed clinical features are summarized in 
Table 1).  
As non-neoplastic tissues (normal controls), we selected 8 cases of FFPE healthy gastric 
mucosa from patients subjected to pancreatic duodenectomy for pancreatic cancer.  
The number of cases was increased with a second independent cohort of 61 EAC 
patients from The Academic Medical Center Hospital (Amsterdam, Netherlands). 
Patients underwent upper gastrointestinal endoscopy during which three mucosal 
biopsies were taken next to each other from the tumor area of patients. Biopsies were 
immediately frozen and stored at -80 °C until RNA was extracted with an optimized 
protocol for selective isolation of microRNAs. As non-neoplastic tissues (normal 
controls), we selected 10 cases of healthy esophageal tissues (fresh-frozen material). 
Histological assessment was performed on biopsies and clinical features are 
summarized in Table 4. 25 out of 61 patients were excluded from the Kaplan-Meier 
disease-free survival analysis since they underwent neoadjuvant chemoradiotherapy 
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following CROSS strategy, including carboplatin, paclitaxel and 41.4Gy of 
radiotherapy, followed by surgical resection.  
The study received approval from the Ethical Committee, as specified in paragraph 
3.1.1. 
 
3.2.2 RNA isolation from FFPE surgical specimens 
From FFPE blocks of EAC and normal gastric mucosa, two 10 µm thick sections were 
prepared and specific tumor area was selected by hematoxylin-eosin staining. Total 
RNA was manually isolated from paraffin-embedded tissue samples using 
RecoverAllTM Total Nucleic Acid Isolation for FFPE Kit (Thermo Fisher Scientific) and 
treated with DNase I (Thermo Fisher Scientific) following manufacturer’s instructions. 
RNA was quantified using NanoDrop spectrophotometer (Thermo Fisher Scientific) and 
stored at -80°C. 
 
3.2.3 TaqMan Human MicroRNA Array cards for microRNA 
expression profiling 
MicroRNA expression was firstly profiled in 8 FFPE EAC cases and 8 FFPE healthy 
gastric mucosa (controls) with the TaqMan MicroRNA Array card A2.1/B3.0 (Thermo 
Fisher Scientific) for a total of 754 human different miRNAs. Included on each array 
three TaqMan MicroRNA Assays were used as endogenous controls (U6 snRNA, 
RNU44 and RNU48) for data normalization. 
50 ng of total RNA was reverse transcribed (RT) into cDNA using TaqMan microRNA 
Reverse Transcription Kit and Megaplex RT primer pools A or B (Thermo Fisher 
Scientific) in 7.5 µl final volume. A step of preamplification was included as follows: 
2.5 µl of the RT reaction was combined with the matching Megaplex PreAmp Primer 
Pool and TaqMan PreAmp Master Mix (Thermo Fisher Scientific) in a final volume of 
25 µl. Preamplification was run using the following cycling conditions: 10 min at 95°C; 
2 min at 55°C; 2 min at 72°C; 15 sec at 95°C, 4 min at 60°C for 12 cycles; 99°C for 10 
min. The preamplification product was diluted 1:4 in TE 0.1X and 9 µl of each dilution 
was combined with TaqMan Universal Master Mix, NoAmpErase UNG (2X) (Thermo 
Fisher Scientific) before loading on the matching TaqMan MicroRNA Array Card. The 
TaqMan Array Cards were spun, sealed and then run on a 7900 HT Real Time PCR 
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system (Thermo Fisher Scientific) using universal cycling conditions (10 min at 95°C; 
15 sec at 95°C, 1 min at 60°C, 40 cycles).  
Raw data files were analyzed using the SDS v2.2 software (Thermo Fisher Scientific), a 
data analysis tool that can quickly evaluate large sets of data files and allows to perform 
relative miRNA expression quantification (2-ΔΔCT method). 
 
3.2.4 Quantitative real-time PCR validation of microRNA profiles 
through single assays 
Real-time quantitative PCR analysis of two miRNAs, that were found to be 
differentially expressed in the microarray experiments on microfluidic cards, was 
validated using single TaqMan probes for miR-221 and miR-483-3p (Thermo Fisher 
Scientific). Expression levels of selected miRNAs were firstly evaluated on 112 FFPE 
cases and then on 61 EAC fresh-frozen tissues. 
Single-strand cDNA was synthesized from 150 ng of total RNA extracted from FFPE 
sections using specific 5X miRNA primers (TaqMan MicroRNA Assay, Thermo Fisher 
Scientific) and the TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher 
Scientific). For fresh-frozen samples, we started from 150 ng of microRNA-enriched 
samples. A step of preamplification was included as follows: 2.5 µl of the RT reaction 
was combined with specific primer pool, containing a 20X mix of forward and reverse 
primers (final concentration of each assay equals 0.2X), and TaqMan PreAmp Master 
Mix in a final volume of 25 µl. Preamplification was run using the same cycling 
conditions specified in paragraph 3.2.3.  
The preamplification product was diluted 1:8 in TE 0.1X then 2 µl was combined with 
TaqMan Universal Master Mix II, NoAmpErase UNG (2X) and specific 20X TaqMan 
MicroRNA Assays for miR-221 and miR-483-3p (#000524, #002339). Quantitative 
PCR (qPCR) analysis was performed on 7500 Fast Real-Time PCR Systems (Thermo 
Fisher Scientific) using universal cycling conditions (10 min at 95°C; 15 sec at 95°C, 1 
min at 60°C, 40 cycles). PCR reactions for each sample were run in triplicate. Control 
reactions included cDNA synthesized without reverse transcriptase enzyme (RNA only) 
and no cDNA template. RNU44 (#001094) was tested as endogenous control for data 
normalization. Fold change was calculated using 2-ΔΔCT method, comparing FFPE 
tumor cases versus the pool of 8 selected tissues of healthy gastric mucosa, or 
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comparing fresh-frozen cases versus a commercial pool of normal esophagus RNAs 
pooled from 5 different donors (BioChain, Newark, CA, USA).  
 
3.2.5 Immunohistochemistry (IHC) 
4 µm sections of FFPE tissue were used for IHC of SMAD4 and PTEN antigens, using 
the following antibodies: SMAD4 mouse monoclonal antibody (clone B-8, 200 µg/ml, 
diluted 1/200; Santa Cruz Biotechnology) and rabbit anti-human PTEN antibody 
(Clone: SP128; Abcam, Cambridge, UK). 
PTEN immunohistochemistry was performed using the Ventana automated staining 
platform (Ventana Medical Systems), instead SMAD4 IHC was performed manually. In 
brief, deparaffinized sections were immersed in 3% H2O2 for 10 min to abolish 
endogenous peroxidase activity and washed in 0.05 M TBS (pH 7.3) for 15 min. 
Antigen retrieval was performed in citrate buffer (pH 6.0) in a microwave oven with 
one cycle at 900 W for 3 min followed by a second cycle at 360 W for 13 min. Sections 
were then incubated with specific antibody for 1 hour at room temperature. The slides 
were subsequently rinsed three times in TBS and incubated for a further 20 min with 
Multilink Biotinylated anti-Ig (Biogenex) diluted 1:20, followed by 3 min incubation 
with 0.05% 3-3'-diaminobenzidine-tetrahydrochloride in 0.02% H2O2. Sections were 
finally counterstained with Mayer's hematoxylin, dehydrated and mounted. The 
immunohistochemical analysis was validated using both positive controls (non-
neoplastic mucosa and lymphoid cells) and negative internal controls (i.e. smooth 
muscle cells admixed with tumor).  
The expression of the SMAD4 protein was defined by a complete loss of expression in 
at least 30% of cancer cells, using the same cut-off score identified for colon cancer in a 
previously published work [103;104]. 
Instead, a tumor tissue was considered to have PTEN protein loss if the intensity of 
cytoplasmic and nuclear staining was markedly decreased or entirely negative across 
>50% of tumor cells compared to surrounding benign glands and/or stroma, which 
provide internal positive controls. If the tumor showed PTEN protein expressed in 
>50% of sampled tumor glands, the tumor was scored as PTEN intact.  
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3.2.6 Cell lines 
To perform functional studies of the expression profiles of both miR-483-3p and miR-
221, found dysregulated in our patients’ cohorts, we used 2 EAC cell lines: OE19 and 
FLO-1 [105].  
Both cell lines were provided by Professor Kausilia K. Krishnadath of Academic 
Medical Center Hospital, Amsterdam, Netherlands.  
The cell line OE19 was established in 1993 from an adenocarcinoma of gastric 
cardia/esophageal gastric junction of 72 yeas old male patient. The tumor was identified 
as pathological stage III (UICC TNM classification) and showed moderate 
differentiation [105;106]. The FLO-1 cell line was established from a primary distal 
esophageal adenocarcinoma in a 68 years old Caucasian male in 1991. The tumor was 
classified as pathological stage III, poorly differentiated [105;107]. The mutational 
landscape of these cell lines was known and representative of EAC tumors [108]. 
OE19 cells were cultured in RPMI 1640 (EuroClone, Milan, Italy) supplemented with 
10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2mM 
L-glutamine (supplements were purchased from Sigma-Aldrich). Instead, FLO-1 were 
grown in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) (EuroClone) 
supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 2mM L-glutamine (Sigma-Aldrich). All cells were cultured in a 5% 
CO2 incubator at 37°C.  
 
3.2.7 Reverse transcription PCR and real-time quantitative PCR 
analysis of SMAD4 
Total RNA was extracted from FLO-1 and OE19 cells using Invitrogen™ RiboPure™ 
RNA Purification Kit (Thermo Fisher Scientific) and retrotranscribed with Maxima H 
Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). TaqMan gene 
expression assays (Thermo Fisher Scientific) were performed following manufacturer’s 
instructions. The assays utilized were SMAD4 (Hs00929647_m1) and β-actin 
(Hs99999903_m1). qPCR analysis was performed on the 7500 Fast Real-Time PCR 
Systems (Thermo Fisher Scientific) using universal cycling conditions (10 min at 95°C; 
15 sec at 95°C, 1 min at 60°C, 40 cycles). Relative gene expression was normalized to 
β-actin by comparative Ct method (2-ΔΔCT).  
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3.2.8 Wound healing assay 
5x105 esophageal tumor cell lines (OE19 and FLO-1) were plated onto six-well plates 
and allowed to form a confluent monolayer. The cell monolayer was scratched in a 
straight line to make a ‘scratch wound’ with a 10-µl tip and the cell debris was removed 
by washing the cells with phosphate-buffered saline (PBS). Images of the wound 
closure were captured at 0 and 3 days. Images were analyzed with the TScratch 
software [109]. 
 
3.2.9 Statistical analysis 
Expression data from MicroRNA Arrays was analyzed with the statistical software 
Expression Suite Software v.1.0 (Life Technologies). The software included the 
student’s t-test for sample group comparisons and built Volcano Plot comparing the size 
of the fold change to the statistical significance (P-value).  
The ROC method was used to optimize cut-off values for miRNAs classification into a 
“high expression” and “low expression” groups.  
Correlations between miRNA expression, tumor recurrence, cancer specific death, 
BIM/GIM and Lauren’s classification were investigated using Mann-Whitney and 
Kruskal-Wallis tests, t-Student’s test and Kaplan-Meier method, using SPSS (version 
15.0; SPSS Inc., Chicago, IL, USA). 
Student’s t-test using Prism (GraphPad, San Diego, CA, USA) was performed to 





4. Results Part I 
 
 
4.1 Genomic profiles of primary and metastatic esophageal 
adenocarcinoma identified via digital sorting of pure cell 
populations: results from a case report 
In order to evaluate the importance of tumor cell selection for an unambiguous genetic 
analysis, we started studing the case of a woman who underwent primary radical 
resection for a stage 2B HER-2-positive Barrett’s type esophageal adenocarcinoma 
(EAC) (detailed clinical features are summarized in Table 1, Row 1, EAC1). Despite 
HER-2 targeted therapy, her disease recurred and required repeated metastectomies.  
Whole Exome Sequencing (WES) of the primary EAC and first two metachronous lung 
metastases (M1 and M2, resected in April and December 2015 respectively) reveled a 
shared heterozygous TP53 missense mutation (chr17:7577094 G>A), that caused a 
single amino acid substitution (NP_00537:p.Arg282Trp, rs28934574; Figure 8A). 
Sanger sequencing confirmed the presence of the variant as heterozygous in the EAC 
primary tumor and in two metastases, but it was absent in the patient’s blood DNA, 
indicating that is a somatic mutation (Figure 8B).  
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Figure 8: TP53 p.Arg282Trp mutation. A. Representation of the TP53 mutation (Integrative Genomic 
Viewer, IGV). B. Sanger sequencing of EAC, metastasis and blood. 
 
 
The TP53 variant maps in one of the 6 “hotspot” residues frequently mutated in tumor 
cells and it is present in the COSMIC database (https://cancer.sanger.ac.uk/cosmic; 
COSM10704), where it has been found in different tumor samples (544 entries), 
including stomach and lung carcinoma. It is present in large control databases such as 
1000G, ExAc and GnomAD at an extremely low allele frequency (MAF= 0.00002) and 
it is predicted to be associated with cancer (score -9.73) by FATHMM 
(http://fathmm.biocompute.org.uk). It is also reported in ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar) as a pathogenic germline allele (id 27403) 
present in patients with Li-Fraumeni’s syndrome, characterized by the development of 
different tumors in the affected individuals (OMIM #15623).  
Hematoxylin and eosin (HE)-stained slides from all FFPE blocks of primary tumor and 
metastases showed homogenous clusters of cancer cells (Figure 9A), which revealed an 
intense immunohistochemical staining for p53 compared to the normal counterparts, 
that was consistent for TP53 missense mutations (Figure 9B). 
 




Figure 9: A. Histological appearance of the primary EAC (hematoxylin and eosin staining). B. p53-
immunoreactivity in primary EAC. 
 
 
In order to dissect the real zygosity status of this variant, cancer cells were separated 
from stromal cells, using the DEPArrayTM (Menarini Silicon Biosystems) sorting 
protocol. Using this technology, 9 cancer and 9 stromal populations were isolated in the 
EAC primary tumor and the two metastases (Table 5). All tumor populations showed a 
DNA index higher than 1, suggesting a hyperdiploid DNA content and confirming their 
tumor origin. Targeted sequencing, performed at deep coverage (mean depth ranged 
between 600X and 5000X) using the OncoSeek Panel (Menarini Silicon Biosystems), 
revealed that TP53 was completely mutated in the EAC and metastatic clusters, whereas 
it was wild-type in the stromal cells (Figure 10 – row 13). This suggested that the TP53 
locus might have been involved in an early loss-of-heterozygosity (LOH) event.  
The purity of the sorted samples also detected several LOH events involving the cancer-
related genes on chromosome 4 PDGFRA, KIT (Figure 10 – row 1-6), and on 
chromosome 7 CDK6, MET in the primary EAC and in the analyzed metastases (Figure 
10 – row 7-12). In these cases, LOH events were characterized by allele frequencies 
near 50% in stromal populations (germline heterozygous sites), that deviate to 0% or 
100% in pure tumor populations.  




Figure 10: Relevant variants identified in the sorted pure populations of tumor (red), stromal (blue) cells 
and unsorted fractions (violet) from primary EAC and two chest metastases. Table cells in grey highlight 
positions with very low coverage. Numeric values represent the alternative allele frequency. 
 
 
To confirm the presence of LOH regions, we performed B-allele frequency (BAF) 
analysis on WES data. Despite the lower purity of data, the BAF profiles of EAC 
primary tumor sample were consistent with the identified LOH events, whose 
coordinates insisted on long regions of polymorphic markers with allelic frequencies 
that mostly deviate from heterozygous value (Figure 11). 
 
 
Figure 11: BAF plot obtained using WES data of the primary EAC and a control female individual (WES 
performed on genomic DNA derived from peripheral blood). In the tumor track, the green lines highlight 
the positions of genes with putative LOH events detected using the OncoSeek panel. While the control 
profile shows a flat signal centered around 50%, as expected for a normal germline DNA, EAC tumor 
profile highlights several consistent regions with abnormal allele frequency, describing putative copy-
number altered regions. Given the high variability of allele frequency, due to the relative low coverage in 
WES, a local smoothing on 20 Mb-long regions, represented by red dots, was calculated specifically to 
mitigate the frequency variability and to give a sharper idea of copy-number alterations at genome-level. 
 
 
In addition to TP53 mutation and LOH events, an ERBB2 intronic variant were also 
detected (chr17:37858678 A>G, rs1565923; Figure 10 – row 14), that showed a ~ 100% 
frequency in both tumor populations and unsorted samples, indicating a high level of 
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copy-gains. Conversely, TP53 (Figure 10 – row 13) did not show such a prevalence of 
the mutated allele in the unsorted fraction (frequency ~ 50%), suggesting that it did not 
undergo the same amplification event as ERBB2. In concordance, DEPArrayTM 
OncoSeek copy-number analysis of the sorted cell populations revealed a high level of 
ERBB2 amplification in all tumor subpopulations, that was completely absent in sorted 
stromal cells (Figure 12). Interestingly, in the sorted cell populations the ERBB2 fold-
change decreased from ≅70-fold in the primary tumor to approximately ≅45-fold in the 
two recurrent chest metastases that subsequently developed. Statistical analysis revealed 
that the fold-changes were significantly different between primary tumor and two 
metastases (one-way ANOVA, p < 0.01 M2/PT, p < 0.05 M1/PT; Figure 12).  
A further confirmation of ERBB2 amplification derived from the copy number analysis 
performed with EXCAVATOR2 software using WES data of unsorted material, even if 
the absolute value of the amplification in primary EAC and in metastases was much 
lower due to normal cells contamination (Figure 13, Table 6, chr17:37263657-
38948823).  
Despite the “diluting” effect due to stromal cells, by performing analysis of copy 
number alterations (CNA) on the whole primary tumor and metastases, a gain of the 
chromosomal region 6q21–22.33 (18 Mb) was detected. This alteration in the second 
chest metastasis generated a focal amplification (39 copies) spanning RNF146 and 
ECHDC1 genes (Figure 14; Table 6). ECHDC1 copy gains are already present in 
COSMIC database (COSG94494; http://cancer.sanger.ac.uk/) in one case of esophageal 
cancer.  




Figure 12: ERBB2 fold-change in all sorted pure populations (stromal and tumor) of primary EAC (PT) 
and two metachronous metastases (M1 and M2). Histogram of CNV differences in the primary EAC and 




Figure 13: Her-2 Copy-number analysis using EAC WES data on unsorted material. 
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Figure 14: Plots of copy number analysis using WES data. The 18 Mb region on chromosome 6 (q21-
22.33) is indicated in the red box, where CNA analysis identified a copy gain in PT (primary tumor) and 
M1 (first metastasis). In the second chest metastasis (M2) a focal amplification was detected in the 
6q22.33 region, spanning RNF146 and ECHDC1 genes (black arrowhead). 
 
 
Using routine diagnostic techniques, no differences were observed in HER-2 
immunostaining between the primary lesion and chest metastases (Figure 15A). Silver 
in situ hybridization (SISH) showed clusters of ERBB2 amplification, shared by primary 
and metastatic tumor sites, with a ERBB2/CEP17 > 2 and ERBB2 copy number > 6 
(clusters). However, differences between samples could not be appreciated with SISH, 
since all tissues presented the same amplification patterns (Figure 15B). 
 





Second chest metastasis (M2) 
First chest metastasis (M1) 
EAC (PT ) 
ii
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First chest metastasis (M1)






Figure 15: Diagnostic techniques to detect ERBB2 amplification A. (i) Histological appearance and Her-
2-immunoreactivity in the primary EAC (i-ii), M1 (iii-iv) and M2 (v-vi) metastases. B. Her2 cluster 
amplification detected by Ventana’s Her2 SISH test in primary EAC (i), M1 (ii) and M2 (iii) metastases. 
Clusters of amplification are represented by black areas in the nuclei. 
 
 
Whole exome sequencing performed on the third metastasis (M3, resected in July 2018) 
confirmed the presence of the TP53 missense mutation (p.Arg282Trp) and the ERBB2 
amplification previously identified, with the same fold change as second metastasis.  
In addition, we identified two neighboring variants of new onset, hitting SMARCA4 
gene on chromosome 19 (chr19:11169553 G>T and chr19:11169554 G>T). While the 
first variant causes a synonymous substitution (NM_001128845 p.L1511L), the second 
one is a nonsense mutation that introduces a stop codon (p.L1512*). This variant is not 
present in control databases such as GnomAD but it is already reported in COSMIC 
database (COSM6972998; https://cancer.sanger.ac.uk/cosmic) in squamous cell lung 
cancer. Other variants in the same gene are reported in esophageal adenocarcinoma and 
esophageal squamous cell cancer (from TCGA database; https://www.cancer.gov/about-
nci/organization/ccg/research/structural-genomics/tcga).  
These SMARCA4 variants are found on the same allele and form a haplotype (Figure 16) 
present in 28 out of 194 total reads (alternative allele frequency of 15%, Figure 16), 
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indicating the possible presence of an advanced tumor subclone, possessing this 
alteration. This hypothesis was confirmed by Sanger sequencing of bacterial colonies 
after the TA- cloning step was carried out to separate the two alleles. Thus, we were 
able to clearly isolate the mutated allele showing the GG> TT substitution (Figure 17), 
predicted to produce a premature SMARCA4 protein termination, with a polypeptide 
missing part of its bromodomain. 
 
 
Figure 16: Representation of the SMARCA4 mutations (Integrative Genomic Viewer, IGV), identified in 


















Figure 17: Sanger sequencing of individual recombinant bacterial colonies, where exon 32 of SMARCA4 
gene was cloned. In the upper panel, the electropherogram show the wild-type allele, whereas in the lower 
panel, the electropherogram show the mutant allele, carrying the GG> TT substitution.  
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Additionally, SNP-based phylogenetic analysis with SNPhylo, using the WES data, was 
performed and a phylogenetic tree was constructed to see how similar the three 
metastases and how differ from primary tumor. Results revealed that all three distant 
metastases descended from a common metastatic precursor, derived from the primary 
tumor, and two of them (M1 and M2) clustered together to finally diverge in two 
branches from a shared precursor clone. The first two chest metastases (M1 and M2) 
presented the same phylogenetic distance from primary EAC, given by the sum of each 
branch length between samples. Instead, the third metastasis (M3) seems to have shorter 
evolutionary distance from primary tumor, in terms of numbers of substitutions events 










Figure 18: SNPhylo analysis results, showing the genetic distance between the four tumor samples. 
Numbers indicate the branch length from central node. The distance between two tumors is equal to the 
sum of their branch length. 
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4.2 High-throughput sorting of tumor cell populations reveals 
the composite mutational landscape of esophageal 
adenocarcinoma 
To further improve the genetic characterization of esophageal adenocarcinoma (EAC), 
pure tumor cell populations were separated through high-throughput cell sorting 
technology from formalin embedded material (FFPE) of 38 EAC patients, who were 
treated with surgery alone (Table 1, patients indicated by “*”). The cells obtained from 
each block were sorted based on immunoreactivity to antibodies against 
vimentin/cytokeratin and DAPI signal, that is proportional to DNA index (DI), using 
DEPArrayTM machine (Menarini Silicon Biosystems). Thus, we identified at least two 
cell populations: the stromal (vimentin positive) and the tumor population (cytokeratin 
positive).  
Target sequencing results for the DNA extracted from the whole-tumor samples and 
sorted cells was performed for 63 cancer-related genes, using the OncoSeek Panel NGS 
approach (Menarini Silicon Biosystems). Data analysis was performed on a dedicated 
pipeline, comparing stromal and tumor cell population sequencing data. The same 
analysis was performed on unsorted cells using the whole tumor specimen. All variants 
identified were filtered according to presence/absence in public databases (1000 
Genomes, gnomAD, COSMIC) and their pathogenic effect. 
61 point mutations (missense, nonsense and frameshift) were found across 63 genes by 
targeted sequencing of the unsorted samples, and 9 additional somatic mutations were 
detected in the sorted tumor cells (Figure 19A).  
The allele frequencies of gene mutations were greater in the sorted cells, where the 
majority of variants were found in a homozygous state (the number of reads supporting 
the alternative allele was >80%). Instead, the analysis of unsorted heterogeneous tumor 
samples revealed an abundance of low-frequency genetic variants (under 20%) that 
were below the limit of detection of conventional NGS analysis at lower coverage 
(below 4000X) (Figure 19B). Furthermore, in 5 cases (EAC13, EAC14, EAC19, 
EAC33 and EAC35), mutations in HNF1A, in PTEN, in TP53 and STK11 were missed 
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Figure 19: Point mutations detected through 
sorted cells sequencing and unsorted cells 
sequencing. A. Number of point mutations, 
distinguishing between missense (blue), 
nonsense (orange) and frameshift (grey), 
identified by targeted sequencing in sorted and 
unsorted cells. B. Number of point mutations 
identified in sorted (blue) and unsorted (orange) 
cells, clustered in 4 categories according to the 




4.2.1 Copy number alteration analysis 
Although the majority of recovered cancer populations (CK+/VIM-) showed a DI 
higher than 1, indicative of hyperdiploid DNA content, other cell populations positive to 
CK immunostaining showed a pseudodiploid DNA content (DI=1), resembling the 
profile of normal cells. In particular, in 13 EAC cases, we were able to isolate both 
hyperdiploid and pseudodiploid tumor clones. Low-pass whole-genome sequencing 
analysis was used to verify whether pseudodiploid cells (isolated in 9 of 13 EACs with 
different tumor populations) also showed an aberrant genomic profile, as expected for 
cancer cells. Among these 9 cases, two (EAC10 and EAC18) keratin-positive 
pseudodiploid cell populations through low-pass sequencing confirmed a normal copy 
number profile (true-diploid) resembling the corresponding stromal cells, whereas the 
other 7 cases showed aberrant genomic profiles (Figure 20). In these 7 cases, the sorted 
tumor populations showed different single-nucleotide mutational loads, and in two cases 
(EAC19 and EAC4) additional CNAs were also detected in hyperdiploid cells compared 
to those identified in the corresponding pseudodiploid populations. It is likely that these 


















































































































Figure 20: High-throughput image-based cell sorting and analysis of recovered cell populations. 
Clustering of copy number alteration (CNA) profiles inferred from low-pass whole-genome sequencing 
for different cell populations for 9 EACs, sorted based on antibodies against vimentin (V)/cytokeratin 
(CK) and based on the DAPI signal, proportional to cell ploidy. Gains and losses with respect to the 











Figure 21: CNA analysis of recovered cell populations from EAC19. A. Low-pass whole-genome profile 
(chr1-22 and chrX) for 2 keratin-positive cell populations (L4356, pseudodiploid cells, green box; L4357 
hyperdiploid cells, red box) sorted from sample EAC19. Ploidy values are indicated on the y-axis; on the 
x-axis, the alteration of different chromosomes is plotted with different colors. CNAs in the tumoral cells 
are indicated in red (amplification) and blue (deletion). B. Principal CNAs identified in pseudodiploid 
(L4356) and hyperdiploid cell populations (L4357) in EAC19. An approximate copy number value is 
indicated in brackets. 
 
 
4.2.2 Identification of mutations in TP53 and p53-regulated genes 
Upon cell sorting, at least one somatic alteration across 63 cancer related genes (point 
mutation, small insertion/deletion or copy-number alteration), was detected in 35 out of 
38 EAC analyzed (Table 7). In 5 EAC cases, only one somatic gene mutation or CNA 
was detected, whereas the remaining cases presented alterations in multiple genes 
(Table 7).  
In 28/38 (73.7%) of cases a mutation in TP53 was detected and in 4 cases we observed 
mutations in CDKN2A, a p53-regulator (Table 7). The TP53 p.R273H hotspot mutation, 
found at a low percentage in unsorted tumor tissue samples of EAC6, EAC11 and 
EAC26, and the nonsense mutation in CDKN2A (p.R58*), detected in sample EAC4, 
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were also confirmed by Digital Droplet PCR (ddPCR), which we used as an 















Figure 22: TP53 and CDKN2A mutations identified in different patients with OncoSeek panel and 
validated by Droplet Digital PCR (ddPCR) specific assays. In the left panel; TP53 hotspot mutation 
(p.R273H) identified by the targeted panel in the sorted pure populations of the tumor with hyperdiploid 
(violet) and pseudodiploid (brown) DNA content and in unsorted fractions (gray) of 3 EAC samples 
(EAC6, EAC11 and EAC26). Values represent the alternative allele frequency. The graph shows TP53 
mutant allele fractional abundances (%) identified with ddPCR in the DNA from unsorted material of 3 
EACs, a known wild-type sample and a no-template control (NTC). In the right panel; CDKN2A nonsense 
mutation (p.R58*) identified by targeted panel in the sorted pure hyperdiploid cell population of tumor 
(violet) and in unsorted fractions (gray) of sample EAC4. Values represent the alternative allele 
frequency. The graph shows the CDKN2A mutant allele fractional abundance (%) identified with ddPCR 
in the DNA from unsorted material of EAC4, a known control wild-type sample (CTR wt) and a no-
template control (NTC). 
 
 
A total of 24 different TP53 mutations, involving distinct aminoacid residues, were 
detected in our EAC samples. Investigation of the type of these mutations showed that 
the vast majority were missense mutations (16/24; 66.67%; Figure 23A), two of which 
are classified as functional in IARC TP53 Database (http://p53.iarc.fr/) based on overall 
transcriptional activity (TA) (Figure 23B) [110], followed by frameshift (5/24; 20.83%) 
and nonsense mutations (3/24; 12.5%; Figure 23A; Table 8). The mutations were found 
to be quite diverse with respect to the location across the coding region of the gene; 
however, they occurred preferentially in the DNA-binding domain of p53 protein 
(aminoacids 101-300) (Figure 23C). Whereas single heterozygous TP53 mutations were 
present in 35.7% (10/28) of patients with mutant TP53, homozygous TP53 mutations 
were detected in 64.3% (18/28). Thus, a lower proportion of wild-type TP53 allele 
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retention was detected because of more frequent 17p LOH events or second 
heterozygous TP53 mutations. In 5 cases where we isolated two tumor populations, in 
the hyperdiploid tumor clones we observed the complete loss of TP53 wild-type allele 
and the selective retention/duplication of mutant allele compared to the respective 
clones with lower DNA content where the mutations were detected in heterozygous 
state. Thus, we confirmed the presence of multiple tumor clone at different progression 
stages and high frequency of LOH events at TP53 locus during esophageal 









































Figure 23: TP53 mutations distribution graphs. A. Mutation effect. Proportion of mutations classified 
according to their predicted effect on protein sequence (missense, nonsense, frameshift ins/del): number 
of mutations of each class divided by the total number of mutations detected (% is shown). B. 
Transactivation. Proportion of missense mutations classified according to their experimentally measured 
transactivation activities (based on IARC TP53 Database): number of mutations of each class divided by 
the total number of missense mutations detected (% is shown). C. Codon distribution. Proportion of 
exonic point mutations at each codon position: number of mutations at each codon position divided by the 
total number of exonic mutations detected (% is shown). 
 
 
In all 38 cases immunohistochemical (IHC) analysis was performed for the p53 protein, 
which has long been used as a surrogate method for mutations analysis in 
histopathological diagnostic practice [111]. A significant correlation was observed 
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between p53 protein overexpression by IHC and the presence of missense mutations, in 
line with previous data (P = 0.0002, Fisher’s test; Tables 8 and 9; Figure 24A, B) 
[112;113]. In 10 EACs, that did not show p53 overexpression, 5 truncating mutations 
(stop-codon or frameshift changes) and three missense changes classified as 





Figure 24: A. Immunohistochemistry indicating low p53 protein expression in a case with a normal p53 
gene status (hematoxylin was used as a counterstain). B. Immunohistochemistry for p53 in a case of gene 
missense mutation and protein overexpression. 
 
 
4.2.3 Selective sorting identifies high intra-tumor heterogeneity  
The presence of high intra-tumor heterogeneity, observed with targeted sequencing and 
CNA analysis of sorted cell populations, was also supported by further validation of the 
mutations identified. In particular, in EAC36, the TP53 missense mutation p.Y220C 
was found in 59.77% and 99.86% (Figure 25A) of the NGS reads obtained from the two 
subclones of the sorted tumor cells. We were able to confirm the mutation with Sanger 
sequencing, in two out of three sections from the same FFPE block. Analysis of the 
third section revealed a very low variant allele peak, almost below the detection 
threshold of Sanger sequencing (Figure 25A), due to the presence of different cell types 
within the cancer area. 
Furthermore, a homozygous TP53 mutation was identified (p.R267G) in patient EAC32 
in a homozygous state in the sorted tumor cell population (Figure 25B). Further 
investigation with Sanger sequencing of two different tissue sections from the same 
tumor tissue block identified this TP53 mutation in only the DNA isolated from the 
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unsorted cells of one section, confirming the high intratumor heterogeneity of these 









TP53 	p.R267G 0,00 99,82 31,45
B
V+/K- K+/V-	(DI=1.29) K+/V-	(DI=1.94) unsorted
TP53 	p.Y220C 0,00 59,77 99,86 39,31
 
Figure 25: A. TP53 p.Y220C mutation in the sorted pure populations of hyperdiploid tumor cells (violet), 
stromal cells (blue) and unsorted cell fractions (grey). Values represent the alternative allele frequency 
(upper panel). Lower panel: Sanger sequencing of DNA isolated from three different tissue sections of the 
same tumor tissue block, showing the presence of the mutation as a heterozygous change in only sections 
1 and 2 (red arrow). B. TP53 p.R267G mutation in the sorted pure populations of hyperdiploid tumor 
cells (violet), stromal cells (blue) and unsorted cell fractions (grey). Values represent the alternative allele 
frequency (upper panel). Lower panel: Sanger sequencing of DNA isolated from two different tissue 
sections of the same tumor tissue block, showing the presence of the mutation as a heterozygous change 
in only section 1. 
 
 
4.2.4 Correlation between TP53 mutations and survival 
Since TP53 is the most frequently mutated gene in EAC, we evaluated whether the 
presence of TP53 mutations correlated with clinical outcomes in our cohort of cancers 
not treated with preoperative chemotherapy (naïve cases). Kaplan-Meier method was 
fitted to assess the influence of TP53 on survival. This analysis revealed a correlation 
between the TP53 mutational status and a better cancer-specific survival (Log-Rank P = 
0.028; Figure 26), which, nevertheless, was not statistically significant when we 
considered the p53 protein expression according to IHC (Log-Rank P=0.2). 
Therefore, surgery alone without neoadjuvant chemotherapy/chemoradiotherapy 
resulted in a significant benefit for tumor-associated survival in patients with mutant 
TP53 compared with those with a wild-type TP53.  
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Figure 26: Kaplan-Meier plot of cancer-specific survival, as stratified for patients carrying mutated or 
wild-type TP53 (Kaplan-Meier test; log-rank test P = 0.028). 
 
 
Moreover, a difference in the distribution of TP53 mutations was observed in the 
histological subtypes defined according to Lauren’s classification, i.e. intestinal vs 
diffuse type. In our sample, 77.4% of intestinal cases, a histological type associated with 
better outcomes [53;55;54], had TP53 mutations. Statistically significant differences in 
the frequency distribution of TP53 mutations in intestinal type were observed (χ2 test: P 
= 0.002263), whereas diffuse type cancer did not show this significant increase in 
TP53 mutations (χ2 test: P = 0.7055); however, the number of diffuse cases was small 
(Table 10). The value of TP53 mutations as prognostic factor was also assessed with a 
multivariate analysis using forward stepwise method that allowed us to predict the 
effects on survival of more variables, such as age, sex, TP53 mutational status, Lauren 
classification and the presence absence of intestinal metaplasia (BIM/GIM). The 
multivariate analysis selected the TP53 mutations, the presence of intestinal metaplasia 
and the Lauren intestinal cancer subtype as the only significant prognostic factors, that 
were associated with a longer survival. Among them, the TP53 mutational status was 
the strongest predictor of esophageal adenocarcinoma survival for our group of naïve 
patients. Indeed, the significant negative coefficient (b=-1.235, P<0.0001; Table 11) 
indicated that the hazard rate for death was greater in the TP53 wild-type patients as 
opposed to the mutant TP53 group.  
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4.2.5 SMAD4 loss is associated with cancer recurrence 
Another frequently mutated genes in our EAC cohort was SMAD4, occurring in 10.5% 
of our patients. SMAD4 is an important tumor suppressor frequently altered in cancers 
[114]; therefore, its expression was also evaluated by IHC in 34 of the 38 sequenced 
EAC samples. In four FFPE tissue sections we were unable to perform and analyze IHC 
results due to poor quality material. 
The samples mutated in SMAD4 (EAC12, EAC17 and EAC23) showed a clear signal 
reduction (Figures 27A), that was also observed in a substantial number of cases with 
no mutations in the SMAD4 gene (18/34, 52.9%) (Table 12).  
We then investigated if there was an association between poor clinical outcomes and the 
loss of SMAD4 expression. For this extent, first the EAC patients were classified 
according to SMAD4 immunoreactivity, using a cut-off of 30% of SMAD4 loss in 
cancer area, based on previous works on colon cancer (103;104). Two groups of 
patients were identified according to this cut-off value: tumors with “low” SMAD4 
protein expression (% of loss >30%) and tumors with “high” SMAD4 protein 
expression (% of loss < 30%). Interestingly, a statistically significant correlation was 
observed between the patients’ group with loss of SMAD4 expression and higher risk of 
developing recurrence (P = 0.015, Fisher’s exact test; Figure 27B). Instead, no 
significant correlation was found between the SMAD4 immunoreactivity and specific 










Fisher’s exact test P = 0.015BA
 
Figure 27: A. Case of SMAD4 loss in tumor cells vs normally expressed SMAD4 in non-neoplastic 
glands and in stromal cells (upper left corner) (hematoxylin was used as a counterstain; magnification 
20X). B. EAC grouped according to cancer high SMAD4 (<30% loss of protein expression; green bars) 
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and low SMAD4 (>30% loss of protein expression; blue bars) and disease recurrence. (Fisher's exact test; 
P = 0.015). 
 
 
4.2.6 Identification of mutations in HNF1A, a novel mutated gene in 
EAC  
In addition to TP53, mutations in other genes occurred at lower frequency, including a 
new gene not previously found mutated in EAC: HNF1A, which encodes for a 
transcription factor that acts as a tumor suppressor in pancreatic cancer [115]. Notably, 
two HNF1A mutations were identified: a missense mutation (p.R263C), occurring in a 
residue important for DNA binding (Figure 28A), and a deletion (c.864delG), resulting 
in a frameshift mutation that introduces a premature stop codon (Figure 28B). The 
HNF1A frameshift mutation, identified in the sorted tumor population, was confirmed 
with Sanger sequencing of DNA form unsorted tumor tissue (Figure 28C). The 
mutations in this gene were found in conjunction with mutations in other genes: in one 
case (missense change), this mutation was found in conjunction with somatic mutations 
of PIK3CA, CDH1, SMARCB1, and in the other case, the frameshift change was found 














































Figure 28: HNF1A mutations identified in the sorted populations of tumors with hyperdiploid (violet) and 
pseudodiploid (brown) DNA content and in unsorted fractions (gray). Values represent the alternative 
allele frequency. A. Frequency of the variant allele HNF1A missense mutation p.R263C in the 
hyperdiploid tumor cell population (violet) (upper panel). The variant pathogenicity was evaluated using 
PROVEAN. The protein domains are shown in the lower panel. The missense mutation (red arrow) is 
indicated. B. Frequency of the variant allele HNF1A deletion (c.864delG) in the different sorted tumor 
populations (hyperdiploid in violet and pseudodiploid in brown) (upper panel) and prediction of the stop 
codon inserted by the frameshift mutation into the mutant protein (lower panel). C. Sanger sequencing of 




4.2.7 Identification of additional mutations through Whole Exome 
Sequencing (WES) 
In order to improve our understanding of the genetic landscape of esophageal 
adenocarcinoma, WES analysis was performed on the DNA extracted from the whole 
tumor area of 8 EAC cases; 5 mutated samples at OncoSeek Panel analysis and 3 
negative cases. We started from FFPE-derived DNA of low quality, mostly showing a 
high degree of DNA degradation (QC <0.20). Bioinformatics data analysis of mapped 
reads revealed an average coverage across exome ranged from 20X to 55X (Figure 
29A) and a percentage of the target region covered at least 10X between 80% and 40% 
(Figure 29B). Using the Spearman rank correlation coefficient test we observed that the 
integrity of DNA starting material was directly correlated with the average coverage 
obtained (Figure 30), indicating that the poor quality of DNA extracted from FFPE 
tissues had significantly impaired quality of whole exome sequencing data. 
 











EAC37  EAC36  EAC32  EAC35   EAC33  EAC34   EAC3   EAC8
 
Figure 29: Quality control of WES data. A. In the upper panel, representation of mean coverage per 
sample; in the lower panel, quality of sequencing as assessed by Phred Quality Score (Q20) that 
represents an error rate of 1 in 100, with a corresponding call accuracy of 99%. Higher Q scores indicate a 













Figure 30: Associations between WES mean coverage for each sample and quality of DNA extracted 
from the whole tumor area of 8 EAC cases evaluated using Spearman rank correlation coefficient test.  
 
 
Despite the quality of starting DNA limits the widespread application of WES in 
clinical practice of cancer patients, in this contest we were able to confirm the presence 
of the mutations detected via targeted sequencing analysis of sorted cell populations, 
that showed a higher sequencing-depth (4000X) and a better uniformity of on-target 
coverage, mapping to the coding region of 63 cancer related genes. In particular, using 
WES mutations were identified in CDKN2A (p.L63Q), APC (p.R876*) and TP53 genes 
(p.Y220C, p.R267G, p.C176F, p.A138V, p.V73RfsTer76) in heterozygous state, 
already found with target sequencing of pure tumor cell populations of EAC36, EAC32, 
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EAC35, EAC3 and EAC8, with higher alternative allele frequencies. Nevertheless, 
WES analysis also detected other damaging heterozygous mutations in genomic regions 
of oncology-relevant genes not covered by the target panel (Figure 31), such as: ARID2, 
ATM, MSH6 in EAC33, FLT3, ERBB2 in EAC8, and ALK in EAC3. These genes are 
candidate drug target in human cancers, therefore an early detection of such mutations is 
important in order to personalize a specific therapy.  
 
















































Figure 31: Results of WES performed in unsorted material of 8 EAC cases. Mutations already found with 




5. Results Part II 
 
 
5.1 Identification of deregulated microRNAs (miRNAs) in 
esophageal adenocarcinoma patients through microfluidic 
cards 
miRNA profiles of 8 EAC cases and two pools of 8 normal gastric tissues were 
analyzed using TaqMan MicroRNA Array card A2.1/B3 (Thermo Fisher Scientific). 
Different patterns of expression were observed, ranging from low to high levels 
compared to controls. Using Expression Suite, miRNAs with a fold change (2-ΔΔCT) 
greater or lower than 2 and a p-value 
< 0.05 were considered to be differentially expressed.  
In particular, we observed 26 miRNAs significantly up-regulated and 72 miRNAs 
significantly down-regulated (Figure 32; Table 13). 
 
 
Figure 32: miRNA expression profile in EAC patients versus healthy controls. Volcano plot data from 
TaqMan microfluidic cards. Each dot on the plot is one miRNA. In the top left: miRNAs (green dots) 
with a significant negative change of expression (down-regulated). In the top right: miRNAs (red dots) 
with a significant positive change in expression. 
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Among them, two miRNAs, based on public data available (miRBase: 
http://www.mirbase.org/), resulted of particular interest: miR-221 and miR-483-3p 
(Figure 33). 
Both miR-221 and miR-483-3p resulted significantly up-regulated in our EAC cases, 















Figure 33: Heat map showing the differential expression of miR-221 and miR-483-3p in EAC cases and 
controls. The color key indicates the expression levels from low (green) to high (red).  
 
 
5.2 miRNA 221 and 483-3p expression analysis via single 
assays and correlation with clinical outcomes 
 
5.2.1 miRNAs expression data from FFPE samples 
The miRNA 221 and miRNA 483-3p expression levels were validated in a cohort of 
112 formalin-embedded (FFPE) surgical specimens of EAC patients, treated with 
surgery alone in different European Centers, as mentioned in paragraph 3.2.1, and 
classified according to Lauren and presence/absence of intestinal metaplasia in 
esophagus and in stomach. They were analyzed via single Real-time PCR assays using 
RNU44 as endogenous control. Fold changes were obtained comparing EAC cases 
versus a pool of 8 RNAs isolated from formalin-embedded healthy gastric mucosa. 
The quantitative analysis showed that the expression patters of both miR-221 and miR-
483-3p were consistent with our preliminary miRNA array data. Indeed, these miRNAs 
were increased significantly in EAC cases compared to normal gastric tissues (miR-221 
mean fold increase 2.276, Wilcoxon Signed Rank test: P<0.0001; miR-483-3p mean 
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fold increase 5.964 P<0.0001; Figure 34), suggesting that they may be novel factors 
associated with the development of esophageal cancer. Among them, miR-483-3p 
exhibited the highest up-regulation fold change (5.964) in both microarray and single 






































Figure 34: miR-483-3p and miR-221 expression levels in EAC cases respect to the control pool. The 
values are expressed as fold increase (2-DDCt) with respect to control tissues (FFPE healthy gastric 
tissues), corresponding to the green base line (Wilcoxon Signed Rank test, P < 0.05). 
 
 
5.2.1.1 miRNA 483-3p expression and correlation with clinical features 
In order to explore the role of miR-483-3p in esophageal adenocarcinoma, statistical 
analyses were performed to investigate possible correlations between miRNA 
expression, tumor recurrence, cancer specific death, Lauren classification and the 
presence/absence of intestinal metaplasia in esophagus (BIM) and in stomach (GIM). 
First, using ROC (Receiver Operating Characteristic) curve and Youden index, we 
defined the optimal cut-off value, related to survival (cut-off 3.15), that distinguished 
the patients into a high miR-483-3p expression group and a low miR-483-3p expression 
group. The Kaplan-Meier curve of the two groups showed a reduced disease-specific 
survival in patients with up-regulation of miR-483-3p and EAC cancer (Long-Rank P= 
0.0293; Figure 35A), in particular in Lauren intestinal subtype (Log-Rank P=0.012; 
Figure 35B). Moreover, an increase in expression of miR-483-3p showed a trend toward 
association with recurrence (Mann-Whitney test P=0.05; Figure 36). Significant 
difference in expression was also detected for miR-483-3p among BIM/GIM cancer 
subtypes (overall Kruskal-Wallis analysis P <0.0001; Figure 37), with a specific 
decrease in expression in tumors with Barrett’s intestinal metaplasia (BIM+/GIM-) 
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compared to tumors without intestinal metaplasia (BIM-GIM-) (Mann-Whitney test 
P=0.0002; Figure 37).  
The results of Kruskal-Wallis analysis also revealed that the expression of miR-483-3p 
was quite different among TNM stages, with advanced TNM tumors (stages II and III) 
showing an upregulated miR-483-3p expression (Mann-Whitney test P=0.053 (stages I-
































































Figure 35: Kaplan-Meier curves depict cancer-related survival for groups stratified base on the expression 
levels of miR-483-3p, in all EACs (A) and only in Lauren intestinal subtype (B). 
 
 





































Figure 36: Values of correlations between miR-483-3p and recurrence, using Mann-Whitney test. P-value 




































Figure 37: Values of correlations between miR-483-3p and BIM/GIM classification, using Mann-



































































Figure 38: Values of correlations between miR-483-3p and TNM stages, using Mann-Whitney test. A. 
Differences between stage I and stage II tumors: P=0.053 “*”. B. Differences between stage I and stage 
III tumors: P=0.019 “*”.  
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5.2.1.2 miRNA 221 expression and correlation with clinical outcomes  
To test the predictive value for prognosis, the miR-221 signature was correlated with 
specific clinical features. A ROC (Receiver Operating Characteristic) curve analysis 
was used to identify the optimal cut-off value of fold-change (1.32) that distinguished 
the patients into a high miRNA expression group and a low expression group. 
Subsequently, differences in disease-specific survival were evaluated in patients 
classified into these two groups and patients with high miR-221 expression have shown 
significantly shorter survival compared to patients with low expression (Log-Rank 
P=0.0059; Figure 39A). Kaplan-Meier analysis also revealed a reduced disease-specific 
survival in up-regulated cases showing Lauren intestinal type of EAC (Log-Rank 
P=0.0024; Figure 39B). 
Median expression level of miR-221 was significantly higher in relapsed compare to 
non-relapsed patients (Mann-Whitney test P=0.0003; Figure 40A), and in BIM-/GIM- 
compare to BIM+/GIM- tumors (Mann-Whitney test P=0.0247; Figure 40B). Moreover, 
we compared miR-221 expression patterns at different stages of esophageal 
adenocarcinoma and we found that patients with advanced tumor stages (stage III and 
IV) had significantly higher median expression levels of miR-221 (Mann-Whitey test 
P=0.027 stage I vs stage III, P=0.0146 stage I vs stage IV; Figure 41A,B). 
 

































































Figure 39: Kaplan-Meier curves depict cancer-related survival for groups stratified base on the expression 


































































Figure 40: Values of correlations between miR-221 and recurrence (A) and BIM/GIM classification (B), 
using Mann-Whitney test. P-values were considered significant (P=0.0003, indicated by “***”; 
P=0.0247, indicated by “*”). 
 
 





































































Figure 41: Values of correlations between miR-221 and TNM stages, using Mann-Whitney test. A. 
Differences between stage I and stage III tumors: P=0.027 “*”. B. Differences between stage I and stage 
IV tumors: P=0.0146 “*”.  
 
 
5.2.2 miRNAs expression data from fresh-frozen samples 
We subsequently evaluated the miRNAs expression patterns in an independent cohort of 
61 fresh-frozen EAC biopsies and 10 normal esophageal tissue from The Academic 
Medical Center Hospital in Amsterdam (detailed clinical features are summarized in 
paragraph 3.2.1). The expression analysis was performed using single TaqMan probes 
of miR-221 and miR-483-3p, and RNU44 as endogenous control. The increase in 
expression was confirmed for both miRNAs (Figure 42A,B). Notably, in EAC cases we 
identified a mean fold increase in miR-483-3p and in miR-221 of 2.897 and 14.08 
respectively, which were statistically different in the tumors compared to the control 










































































Figure 42: miR-483-3p and miR-221 expression levels in fresh-frozen tumor samples and fresh-frozen 
control tissues cases. The values are expressed as fold increase (2-DDCt) with respect to a commercial 
control RNAs pool (BioChain), corresponding to the green base line. Statistical comparisons between 
cases and controls was performed (Mann-Whitney test: P<0.0001 (***); P=0.0048 (**)). 
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We tested if the differences in the expression of these two miRNAs could affect the 
patients’ cancer-related survival also in this EAC cohort, in order to confirm our 
previous data (paragraphs 5.2.1.1 and 5.2.1.2). Kaplan-Meier analysis was performed in 
36 out of 61 EAC patients, that were not treated with chemoradiotherapy following 
CROSS strategy.  
Using the ROC (Receiver Operating Characteristic) curve approach to evaluate Youden 
index and associated criterion as a cut-off (miR-483-3p: cut-off £ 0.76; miR-221: cut-
off £ 3.88), the patients were divided into a “high expression” group and “low 
expression” group. In contrast with data obtained in FFPE cohort, no association 
between the expression levels of both miRNAs and poor cancer specific survival was 


















































Figure 43: Kaplan-Meier curves depict cancer-related survival for groups stratified base on the expression 
levels of miR-483-3p (A) and miR-221 (B), as detected by Real Time PCR. We selected patients who 
underwent surgical resection only. P-value are based on Log-Rank test.  
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5.2.3 Expression analysis of SMAD4: a validated target of miR-483-3p  
To explore the mechanisms by which miR-483-3p executes its function in esophageal 
adenocarcinoma, we used public data available in miRBase (http://www.mirbase.org/) 
to identify potential target genes. Among these many candidates, SMAD4 is negatively 
modulated by miR-483-3p, therefore it was selected for further analysis. SMAD4 is a 
tumor suppressor gene and a critical effector of TGFb-pathway, that regulate cell 
proliferation [113], and approximately in 52.9% of EAC cases it was involved in gene 
mutations or loss of protein expression, as mentioned above in paragraph 4.2.5. 
Therefore, we focused on miR-483-3p, hypothesizing that it could directly or indirectly 
target SMAD4, leading to its reduced expression, as previously described in pancreatic 
cancer [116]. To determine whether a similar effect may also be presented in esophageal 
adenocarcinoma, the expression of SMAD4 was evaluated by immunohistochemistry in 
55 formalin-embedded (FFPE) EAC surgical specimens, which were already tested for 
miR-483-3p expression. Loss of SMAD4 protein was defined by complete loss of 
expression in least 30% of cancer cells. Loss of SMAD4 immunoreactivity (IHC) was 
found in 28 out of 55 EAC cases (50.9%) (Table 14), however, except for few cases, we 
did not observe a clear relationship between miR-483-3p up-regulation and SMAD4 
loss (Table 14).  
Since loss of SMAD4 expression was found in several EAC cases, we examined its 
effects on clinical outcomes, i.e. cancer specific survival and tumor recurrence. Kaplan-
Meier analysis showed that loss of SMAD4 immunoreactivity was strongly associated 
with poor survival (Log-Rank: P=0.013; Figure 44A) and recurrence (Log-Rank: 
P=0.001; Figure 44B), suggesting SMAD4 expression as potential prognostic biomarker 
in esophageal adenocarcinoma.  
 


































Figure 44: Kaplan-Meier curves depict cancer-related survival (A) and relapse-free survival (B) for 
groups stratified base on the expression levels of SMAD4 protein. P-value are based on Log-Rank test.  
 
 
5.2.4 Expression analysis of PTEN: a validated target of miR-221  
To determine whether also miR-221 plays a role in esophageal cancer development and 
progression, we focused on PTEN gene, one of its validated target 
(http://www.mirbase.org/) . Notably, PTEN expression was inversely proportional to 
miR-221 overexpression in gastric carcinoma, according to published data [117]. 
Therefore, PTEN protein expression was evaluated by immunohistochemistry in 47 
formalin-embedded (FFPE) EAC surgical specimens, which were already tested for 
miR-221 expression. Loss of PTEN protein, defined by complete loss of expression in 
least 50% of cancer cells, was detected in 40 out of 47 (about 85%) tumor sections 
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(Table 15). Although PTEN expression resulted downregulated in several cases, this 
condition was not correlated with up-regulation of miR-221 in our samples; probably 
other epigenetic mechanisms are involved in PTEN inhibition [118] (Table 15). 
Moreover, no significant correlation was observed between the diffuse loss of PTEN 
protein and survival (Long-Rank: P=0.418). 
 
5.2.5 miRNAs expression analysis in OE19 and FLO-1 EAC cell lines 
The expression of miR-483-3p and miR-221 was further characterized in two different 
esophageal adenocarcinoma cell lines, OE19 and FLO-1, via single Real-time PCR 
assays using RNU44 as endogenous control. 
In both cell lines, there were not significant differences in miR-221 levels (Figure 45A), 
while miR-483-3p expression was absent in OE19 but positively increased in FLO-1 
(fold-change=2.7; Figure 45B). OE-19 and FLO-1 also differed in the expression of 
SMAD4 at RNA level. In particular, we performed SMAD4 gene expression analysis 
with single Real Time PCR assays, using β- actin as reference gene to normalize data. 
Although it did not reach statistical significance, a reduction of SMAD4 expression in 
FLO-1 was observed (Figure 46). Therefore, expression of miR-483-3p and SMAD4 
appear to be inversely correlated in FLO-1 cell line, suggesting the role of this miRNA 






































































Figure 45: miR-221 (A) and miR-483-3p (B) expression levels in FLO-1 and OE19 EAC cell lines. The 
values are expressed as fold increase (2-DDCt) with respect to a commercial control RNAs pool 



































Figure 46: SMAD4 expression in FLO-1 and OE19 EAC cell lines, performed by Real Time PCR. The 
values are expressed as fold increase (2-DDCt) with respect to a commercial control RNAs pool 
(BioChain), using β-ACT as reference gene to normalize data. Statistical comparison between cell lines 






The work described in this thesis aimed to provide novel insights into the pathogenesis 
of esophageal adenocarcinoma (EAC), ranging from genetic profiles to protein 
expression patterns and miRNA signatures.  
Furthermore, we sought to identify potential molecular targets and prognostic 
biomarkers which could lay the basis to detect novel targets for tumor therapy, predict 
the response to conventional treatment regimens and solve crucial controversies on 
EAC classification, supported by studies demonstrating differences in metastatic 
patterns, survival and immune-pathological parameters [29;48]. 
 
Defining the molecular landscape of cancer can be challenging because of tumor 
heterogeneity, therefore in the first part of this thesis we exploited an automatic 
sorting system (DEPArrayTM, Menarini Silicon Biosystems) enabling the isolation of 
pure tumor cell populations for an unambiguous genetic analysis with targeted next 
generation sequencing (NGS).  
 
We first performed a pilot study using formalin-embedded (FFPE) tissue biopsies of the 
primary tumor and three metachronous chest metastases derived from a 53-year-old 
woman affected by an aggressive adenocarcinoma of the esophagus. 
Whole exome sequencing (WES) analysis of the primary tumor and all metastases 
revealed a shared heterozygous TP53 missense mutation (p.Arg282Trp), that was 
completely absent in patient’s blood DNA, indicating that is a somatic mutation. 
Combining cell sorting and NGS analysis we found that the TP53 mutant allele was 
completely mutated in the EAC and metastatic clusters, while it was wild-type in the 
separated stromal cells. This suggests that the TP53 locus might have been involved in 
an early loss of heterozygosity (LOH) event in primary tumor cells, which can explain 
the homozygous state of the p.Arg282Trp mutation. This is in agreement with previous 
findings for which TP53 mutations are considered an early genetic event in Barrett’s 
esophagus associated with an increased risk of progression to cancer [4;57;59]. 
Therefore, from a technical perspective, the high-throughput sorting of the tumor cells 
led to the identification of somatic alterations without a “diluting” effect due to the 
presence of normal stromal cells. Since WES was carried out on whole tumor areas, the 
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presence of “normal” stromal cells within a mixed sample, such as a heterogeneous 
tumor tissue, prevented the identification of the real mutational status of the variant. In 
addition, the possibility to sort and recovery pure stromal cells provided an ideal 
internal control to avoid many false-positive alterations not specific to the patient’s 
tumor [90] and represents a valuable surrogate when matched normal tissue is 
unavailable, as may be the case for archival samples.  
 
In addition to TP53 mutation, we also detected with targeted sequencing and with WES 
an ERBB2 gene amplification, that was completely absent in sorted stromal cells but 
shared by the primary and three metastatic tumor sites. The same amplification event 
was also identified by conventional diagnostic techniques (such as SISH and IHC) and 
had guided the use of anti-HER-2 drug Trastuzumab as the first targeted therapy 
approach. However, as in most Trastuzumab-responsive patients [120], the patient 
developed resistance after four years of treatment. The drug resistance can be due to 
mechanisms dependent on HER-2 receptor, such as overexpression of proteins that 
mask HER-2 receptor (for example, MUC1), up-regulation of target-like tyrosine kinase 
receptors or their ligands, and alternative splicing of ERBB2 [120], or due to HER-2 
independent mechanisms, such as altered PI3K/Akt signalling, deregulation of anti-
apoptotic proteins / cell cycle regulators, TGFβ signalling and epigenetic events 
regulating specific expression pathways, including the immune system signatures 
[120;121;122]. In our case, using the selective cell sorting coupled to NGS, we were 
able to observe that the ERBB2 copy numbers detected were significantly lower in the 
metastases developed after initiation of Trastuzumab therapy, compared to the primary 
tumor, pointing to a selection of sub-clones HER-2 negative, therefore more resistant to 
treatment, although the histological appearance of cells in the tumor areas was 
homogeneous.  
This decrease was not previously detected by standard tests such as SISH or IHC, which 
showed the same clusters of the ERBB2 amplified region in the primary and metastatic 
tissues.  
 
Being located on the same chromosome, TP53 and ERBB2 genes offer further insights 
for understanding the mutational events insisting in chromosome 17. The hypothesis, 
emerging from a combination of WES and target panel data, is that an early LOH event 
of the entire chromosome 17 occurred with prior/following somatic mutation in TP53 
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and large copy-gains of an ERBB2 allele, influencing tumor development and 
progression. These data suggest that all metastases shared a common ancestor with 
TP53 mutation and ERBB2 amplification, and early sub-clonal evolution characterized 
by a partial loss of ERBB2 amplification then occurred. 
 
SNP-based phylogenetic analysis using WES data revealed a genomic divergence 
between metastases, in numbers of substitutions events during cancer progression. This 
is further confirmed by WES data that showed an exclusive focal amplification 
spanning RNF146-ECHD1 genes in the second chest metastasis and a SMARCA4 
nonsense mutation (p.E1512*) of new onset in the third metastasis.  
RNF146 encodes for a E3 ubiquitin ligase ring finger protein 146, a critical regulator of 
Wnt/β-catenin signaling, whose overexpression, reported in non-small cell lung cancer, 
enhances cell growth, invasion, and survival [123; 124].  
ECHDC1 encodes for a proofreading enzyme involved in lipid metabolism, with an 
increased expression observed in resistant bladder cancer cells [125]. We hypothesize 
that the acquired RNF146-ECHDC1 copy gain in the cells giving raise to the second 
metastasis, coupled to the loss of cells with HER2 amplification, might contribute to 
resistance and progression in metastatic EAC cancer. A similar situation can be 
assumed in the third metastasis, where we identified a mutation hitting SMARCA4 gene 
and causing a premature protein termination.  
The SMARCA4 gene encodes a catalytic subunit (BRG1) of SWI/SNF complexes, 
which function as regulators of gene expression by remodeling chromatin to alter 
nucleosome conformation, making it more accessible for transcriptional activation 
[127]. Mutations in SMARCA4 resulting in complete loss of its protein (BRG1) occur 
frequently in non-small cell lung cancer (NSCLC) [127] and the presence of SMARC4-
inactivating mutations increases sensitivity to inhibitors of Aurora kinase A (AURKA), 
a kinase required for mitotic spindle assembly [128;129]. In addition, SMARCA4 
mutations are considered genetic biomarkers that predict enhanced sensitivity to 
topoisomerase II inhibitor (TopoIIi) in response to EZH2 inhibition (EZH2i). In 
particular, tumors with SMARCA4 loss-of-function mutations respond to EZH2i with 
increased apoptosis and TopoIIi sensitivity [130].  
 
Therefore, the genomic dissection of a primary EAC and recurrent metastases allowed 
to identify the tumor cell mutational status and its evolution in response to therapies. 
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Our preliminary study took advantage of an available target panel for cancer-related 
genes, for the study of specific mutations in digitally-sorted cell populations from 
formalin-embedded tissue biopsies. 
 
Based on the results achieved in this pilot study, we exploited this high throughput 
selective sorting technology to investigate the different mutational patterns of 38 EAC 
patients, who were treated with surgery alone. In this line, we were able to investigate 
somatic genomic alterations present in different types of tumor cells without the 
“diluting” effect due to the presence of stromal cells, which were characterized by a 
normal diploid profile. In seven EAC cases different tumor cell populations were 
identified with hyperdiploid or pseudodiploid DNA content, that showed aberrant copy 
number profiles by low pass whole-genome analysis and different somatic mutation 
loads. This finding indicates the existence of different cell clones within the same 
tumor, each of which can have different tumor behavior and responses to therapy.  
35 out of 38 EAC analyzed with OncoSeek Panel carried at least one alteration (point 
mutation, small insertion/delition or copy number alteration), not present in the 
corresponding stromal cells, recovered with the same technology, confirming their 
somatic origin. Most of these mutations, that showed an alternative allele frequency of 
50% in unsorted tumor DNA (heterozygous state), were present as almost unique alleles 
(homozygous state) in the sorted tumor cell populations.  
 
Unexpectedly, mutations in HNF1A, a gene not previously found mutated in EAC, were 
identified in two different samples. HNF1A encodes the protein HNF1α, a transcription 
factor predominantly expressed in the pancreas, kidney and liver [131;132;133]. Several 
proteins are actively involved in the interaction with HNF1α, such as MYC (Myc 
protooncogene protein), HDAC1 (Histone deacetylase 1), CTNNB1 (catenin beta-1), 
TLE1 (Transducin-like enhancer protein1) and PDX1 (Pancreas/duodenum homeobox 
protein 1) [134]. Constitutive mutations in this gene cause maturity-onset diabetes of the 
young (MODY) [135], whereas somatic mutations were frequently observed in 
hepatocellular adenoma [136]. In pancreatic ductal adenocarcinoma, an aggressive 
cancer with poor prognosis, HNF1A acts as a tumor suppressor, and loss-of-function 
mutations in this gene have been reported [115]. A recent study showed that the long 
noncoding RNA HNF1A-AS1 was markedly upregulated in human primary EACs 
relative to that in their corresponding normal esophageal tissues, and HNF1A-AS1 
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knockdown significantly inhibited cell proliferation and anchorage-independent growth 
in in vitro EAC models [137]. However, no mutations in EAC in the HNF1A have been 
reported thus far; therefore, a new gene mutated in EAC was found in this study. The 
mutations identified were found in conjunction with mutations in other genes and we 
expect that lost/mutated HNF1A might contribute to tumor severity/progression. Further 
analyses of additional cases are warranted to investigate the role of this gene in EAC to 
understand whether these mutations might act as a cancer driver or passenger. 
 
Although the considerable level of genetic heterogeneity between patients, the TP53 
gene was confirmed to be the most frequently mutated gene in EACs, as previously 
described [4;56]. The majority of TP53 mutations were shifted to homozygosity in the 
sorted tumor populations, suggesting that they are early events in tumorigenesis, as 
highlighted also by studies in Barrett’s esophagus [57]. Interestingly, in two cases, the 
TP53 mutations were present in ~100% of the sorted tumor cells, but by Sanger 
sequencing they were in heterozygous state only in some of the sequenced DNA 
samples, obtained from different extractions from serial sections of the same tumor area, 
reinforcing the concept of the high intra-tumor heterogeneity.  
 
Mutations in TP53 pave the way for many different molecular derangements that lead to 
diverse histopathological features of the tumors [59]. Thus, a fast and reliable detection 
of its variants is crucial for the accurate diagnostic decisions. Since in routine diagnostic 
pathology of gastric cancer [138] TP53 mutation status is assessed based on p53 
expression by IHC, we also characterized our samples for p53 expression in order to 
verify its ability to define the mutational status. Immunostaining for p53 correlated with 
the presence of missense mutations but could not help us distinguish the presence of 
loss-of-function mutations such as stop codon or frameshift variants from normal p53 
staining, in concordance with previous data [112;113].  
This discrepancy may suggest that a molecular analysis of the TP53 mutational status, 
assessed with sequencing technologies, is of key importance, especially because the 
presence of mutations in TP53 correlated with a better survival in our cohort of EACs. 
However, it is important to note that our patients were not treated with neoadjuvant 
cisplatin/fluorouracil chemotherapy, a treatment associated with poor response when 
p53 is mutated [74;75]. Our data support the idea that the use of cisplatin/fluorouracil 
should be selectively applied preoperatively to patients with wild-type TP53, whereas 
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patients with mutated p53 may benefit more from a timely surgical approach. TP53 
genetic status could be considered a predictive biomarker influencing survival only in 
the presence of effective chemotherapy, also in esophageal adenocarcinoma [73]. 
However, this model is based on a small sample size and further analyses in additional 
treatment-naïve EAC cases will help clarify this important issue in EAC treatment.  
 
Since the complete loss of TP53 wild-type protein in EAC provides a significant impact 
on prognosis and therapeutic options, its pharmacological reactivation emerged as a 
promising strategy for target therapy. Several small molecules that restore wild-type 
activity of mutant p53 have been identified such as APR-246/PRIMA-1Met, which is 
already under clinical trials for different cancers, including EAC [139;140]. This 
molecule restores TP53 activity in presence of missense mutations and regulates several 
TP53-related pathways [139], including the proteasome machinery, a common target of 
TP53 missense mutants. Upregulation of the proteasome fosters chemoresistance to 
proteasome inhibitors and this can be overcome by target p53 mutant proteins with 
APR-246/PRIMA-1Met [141]. Since p53 could be disabled either by mutation or by 
upstream negative regulators, including MDM2, targeting the MDM2-p53 interaction 
by small molecules, like Nutin-3a, could represent an additional therapeutic strategy to 
induced apoptosis in cancer cells with wild-type TP53, as previously described in 
primary B-acute lymphoblastic leukemia [142].  
Therefore, the early identification of TP53 mutation status in EAC is becoming 
increasingly instrumental not only for predicting chemotherapeutic drug response but 
also for selecting more efficient target therapies. In this regard, we suggest to perform 
the mutation analysis of selected tumor cells to determine the real zigosity of the TP53 
variants and the possible presence of a wild-type allele, which could be discriminating 
for some therapies, such as Nutin-3a [142]. 
 
Additional markers may help to characterize tumor progression and among them 
SMAD4 expression was found to be a promising predictive factor for recurrence of 
esophageal adenocarcinoma. Loss of SMAD4 protein expression was a recurrent event 
in EAC, linked with genetic mutations. In fact, all mutated samples showed a clear 
signal reduction, confirming a close correlation between the SMAD4 genotype and the 
protein detection. However, SMAD4 loss was also detected in a number of cases 
without SMAD4 gene mutations (52.9%), and its expression significantly correlated 
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with tumor recurrence, also in absence of gene mutations, indicating that additional 
regulatory mechanisms might be involved, such as promoter hypermethylation, which 
can downregulate SMAD4 expression [86]. These data are in line with previous studies 
on SMAD4 loss in EAC, though those studies identified the immunoreactivity loss in 
fewer cases (10%) [85].  
 
The incorporation of genomic differences in cancer cell sub-populations with currently 
available clinical variables can further stratify patients, in order to select more efficient 
therapeutic options. Moreover, whole exome approach in unsorted material could 
identify additional genomic alterations, compared to targeted sequencing, but not the 
true tumor cell mutational status. Therefore, a promising strategy could be to apply 
whole exome/genome approaches to sorted cell populations from formalin-embedded 
tissue samples, in order to gain a global view of all the tumor alterations.  
 
In the second part of this thesis we aimed to investigate the dysregulated miRNAs in 
EAC, shifting the focus from a genetic to epigenetic characterization of these cancers. 
 
By TaqMan Human MicroRNA Array and single Assays analysis of human EAC 
specimens, we identified a miRNA dysregulated expression pattern in esophageal 
adenocarcinoma tissues compared with esophageal/stomach normal tissues. In 
particular, two miRNAs implicated in tumor progression were found up-regulated: miR-
483-3p and miR-221.  
 
The hsa-miR-483-3 is a mammal-conserved microRNA that resides at the second intron 
of the human insulin growth factor 2 (IGF2) gene at the 11p15.5 chromosome region 
(Figure 47) [143]. The genomic localization of this microRNA is of particular interest. 
Indeed, the IGF2 is an imprinted gene, expressed by the paternal allele to produce an 
important fetal insulin growth factor. Defects in the imprinting of the IGF2 locus are 
observed in the Beckwith-Wiedemann syndrome, which increases the incidence of 
pediatric malignancies as nephroblastoma (Wilms’ tumor), hepatoblastoma, and 
rhabdomyosarcoma [144]. Moreover, adult tumors are linked to genetic and epigenetic 
defects of this imprinted locus such as colorectal cancer, hepatocellular carcinoma and 
breast cancer [145;146], pointing out to IGF2 as the main oncogene of this genomic 
locus. However, a transgenic mouse model for IGF2 (without including the miR-483 
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gene) exhibited several features associated with the Beckwith-Wiedemann syndrome 
without association to any neoplasia [147]. These data suggested the IGF2/miR-483 
locus as the oncogenic unit of the 11p15.5 chromosome region instead of the IGF2 
alone [147]. 
The hsa-miR-483 gene encodes for two mature miRNAs: miR-483-5p and miR-483-3p, 
both found deregulated in different types of cancer. MiR-483-5p is abnormally observed 
in the serum of cancer patients suggesting its possible utilize as circulating cancer 
biomarker in various malignancies [148]. On other hand, the miR-483-3p is extensively 
studied concerning its function on different cancer-related pathways and its expression 
levels is high or extremely high in many common cancer tissues, comprising 30% of 
cases of colon, breast and liver cancer [149].  
 
 
Figure 47: Stem-loop sequence of the hsa-miR-483 and mature miRNAs. In the Figure are reported 
genomic position, sequence of the hsa-miR-483 gene. Sequences data from miRBase database. (adapted 
from: Pepe F et al., 2018 [119]).  
 
 
Together with our findings, it is suggested that miR-483-3p may be used a novel 
biomarker and therapeutic target also for esophageal adenocarcinoma. In fact, miR-483-
3p up-regulation correlated in formalin embedded (FFPE) samples with reduced cancer-
specific survival, in particular in Lauren intestinal subtype. Moreover, statistical 
analysis in FFPE EACs cohort showed an up-regulation of miR-483-3p in cancers 
without intestinal metaplasia in esophagus and in stomach (BIM-/GIM-) compared to 
Barrett’s like (BIM+/GIM-) subtypes. Our data may support a biological difference of 
esophageal adenocarcinoma with or without intestinal metaplasia and between diffuse 
and intestinal subtypes. Further, an increased expression of miR-483-3p was also found 
in advanced cancer stages, suggesting that miR-483-3p signature might contribute to 
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cancer progression and could be used as a prognostic biomarker, in particular in 
Lauren’s intestinal subtype. This correlation highlighted between the expression of 
miR-483-3p and cancer could be justified by its role in cellular pathways such as TGFb 
[119]. In previous works, miR-483-3p was identified in pancreatic cancer as potential 
negative regulator of SMAD4, a tumor suppressor gene that inhibits cell proliferation 
[116]. In fact, comparative analysis of miRNA and gene expression between EAC cell 
lines, revealed an increased expression of miR-483-3p with SMAD4-mRNA reduction 
in FLO-1 cells, although it did not reach statistical significance.  
 
A similar effect was also recognized in EAC due to increased expression of miR-221, a 
cancer-related microRNA [150]. Indeed, miR-221 showed oncogenic properties in EAC 
patients, and correlated with cancer-specific death and recurrence. 
The hsa-miR-221 is located in an intergenic region in tandem with has-miR-222. miR-
221 and miR-222 contain identical seed sequences and both map to the X chromosome 
separated by 727 bases [150] (Figure 48). 
 
 
Figure 48: A: Stem-loop structure of miR-221. B: Genomic localization of miR-221 and miR-221on 
chromosomal band Xp11.3 (Tabasi SA et al., 2009 [150]). 
 
 
The high expression levels of miR-221/miR-222 have been commonly demonstrated in 
multiple human cancer types, as oncomiR [151] or as oncosuppressor-miR [152], 
depending on the cellular context and on the target genes. Overexpression of miR-221 
has important consequences on cancer progression and development: controlling 
proliferative signaling pathways, avoiding cell deaths resulted from tumor suppressors, 
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monitoring angiogenesis and even supporting epithelial-mesenchymal transition [153]. 
These results were confirmed in several cancers, such as thyroid papillary carcinomas 
[154], breast cancer [155], hepatocellular carcinoma [156] and gastric cancer [117]. In 
particular, in gastric carcinoma miR-221 acts as a tumor promoting factor, essentially 
regulating PTEN expression [117]. PTEN is a gene located at 10q23.3 and encodes a 
dual-specificity phosphatase with lipid and protein phosphatase activities. PTEN acts as 
tumor suppressor gene through a variety of pathways and PI3K and AKT are its 
important target genes [157]. In gastric cancer, the overexpression of miR-221 
significantly decreased PTEN protein which should inhibit phosphorylated PI3K and 
AKT resulting in an increase in proliferation, migration and invasion of cancer cells 
[153]. However, a similar effect may not be presented in EAC, where the up-regulation 
of miR-221 was not correlated with loss of PTEN protein. Probably the correlation 
highlighted between the expression of miR-221 and poor prognosis in our EAC samples 
is justified by its role in other cellular pathways.  
 
Further in vitro studies are warranted to elucidate in depth the role of miR-221 and miR-
483-3p in EAC.  
We conducted preliminary studies in EAC cell lines, in particular to understand whether 
miR-483-3p, found dysregulated in FLO-1 cells, can correlate with more aggressive 
tumor phenotype, as observed in our EAC patients. To this aim, we used the scratch 
assay to test the invasive potential of esophageal cancer cells. Wound healing assay at 
72 hours showed that the ability of migrated cells filling a scratch was significantly 
enhanced in FLO-1 cell line compared to OE19 cell line (Student’s t-test P=0.02; Figure 
49A,B), suggesting a possible correlation with upregulation of miR-483-3p. Hence, 
these observations prompt us to further study the functional effect of miR-483-3p via 
transient transfection of individual synthetic miRNA mimics or inhibitors into the 
different EAC cell lines, which can be a useful in vitro model for esophageal 
adenocarcinoma to assess miRNA functions and investigate possible target genes.  
 











































Figure 49: Representative photographs of wound healing assays showed that FLO-1 cells had an 
improvement in wound healing ability at 72h. The statistical results of cell migration area measured by 
Image J software demonstrated a significant difference in cell migration ability. * P=0.02 
 
 
In contrast to other malignancies, such as breast and colon cancer, where the 
incorporation of molecular information has become part of routine practice for 
therapeutic stratification, in EAC the determination of disease stage and grade to guide 
treatment and help classify prognosis is still depending on histological assessments 
[158]. Even though the identification of new molecular biomarkers is still challenging in 
EAC, it is essential to predict patient outcome and facilitate tailored therapies based on 
the molecular profile. 
- Chapter 6- 
 92 
 
To this aim, we used different approaches to investigate genetic and epigenetic features 
in EAC. In order to evaluate the genetic landscape, our studies suggest that cell sorting 
technologies, coupled with next generation sequencing analysis, are ideal tools to guide 
clinical decisions, since they can lead to a better definition of tumor mutation status and 
inter- and intra-tumor heterogeneity.  
Concerning epigenetic factors influencing EAC development/progression, the analysis 
of microRNA profiles seems a promising strategy to distinguish more aggressive 
tumors. MiR-221 and miR-483-3p up-regulation correlated with worst prognosis in our 
tumors, implying that they can be considered oncogenic factors in EAC.  





7. Conclusions  
 
 
In conclusion, our study showed the following:  
 
(i) a combination of high-throughput sorting technology and massive parallel 
sequencing led to a better definition of EAC mutation status, allowing to identify 
mutations in HNF1A, a gene not previously found mutated in EAC, and to reinforce the 
presence of high inter- and intratumor heterogeneity in adenocarcinoma of esophagus. 
 
(ii) we identified genetic and epigenetic biomarkers in EAC, such as TP53, SMAD4 and 
specific microRNAs (miR-221 and miR-483-3p), correlated with tumor recurrence and 
survival. In particular, in our cohort of cancers not treated with neoadjuvant radio- or 
chemotherapy but surgery only, the presence of mutations in TP53, as detected more 
adequately in sorted cells, correlated with better cancer-specific survival (Log-Rank P = 
0.028), and the observed loss of SMAD4 protein (IHC) was statistically significant 
associated with cancer recurrence risk (P-value=0.015). Therefore, the evaluation of 
such markers may help facilitate tailored therapies, and predict patient outcomes in 
terms of survival and recurrence. 
 





Table 1: Clinical and epidemiological information for EAC cases included in the 
study: FFPE cohort. In black: samples from Maria Cecilia Hospital, Cotignola, Italy; in red: 
samples from The Academic Medical Center Hospital, Amsterdam, Netherlands; in blue: samples from 
IRCCS Policlinico San Martino, Genova, Italy; in green: samples from Helsinki University Central 
Hospital, Helsinki, Finland. “*” indicates samples also subjected to genetic analysis. F=Female; M=Male. 
n.a.= not available 
 








Lauren BIM/GIM Stage 
(7thed) 
EAC1 * 53 F 0 72 1 intestinal BIM+/GIM- II 
EAC2 * 43 M 0 60 0 diffuse BIM+/GIM- II 
EAC3 * 76 F 0 1 0 diffuse BIM+/GIM- III 
EAC4 * 66 M 1 36 1 intestinal BIM+/GIM- II 
EAC5 * 71 M 1 11 1 intestinal BIM+/GIM- III 
EAC6 * 82 F 0 84 0 intestinal BIM+/GIM- III 
EAC7 * 83 M 0 27 0 intestinal BIM+/GIM- III 
EAC8 * 86 M 1 13 1 intestinal BIM-/GIM+ III 
EAC9 * 62 M 1 3 1 intestinal BIM-/GIM+ III 
EAC10 * 72 M 1 58 1 diffuse BIM-/GIM+ I 
EAC11 * 76 M 0 12 0 intestinal BIM-/GIM- III 
EAC12 * 58 M 0 53 0 intestinal BIM-/GIM- III 
EAC13 * 28 F 1 22 1 intestinal BIM-/GIM- IV 
EAC14 * 83 F 0 0 0 intestinal BIM-/GIM- III 
EAC15 *  60 F 0 84 0 intestinal BIM-/GIM- II 
EAC16 * 78 M 1 36 1 intestinal BIM-/GIM- II 
EAC17 * 59 M 0 24 1 intestinal BIM-/GIM- II 
EAC18 * 75 M 1 8 1 intestinal BIM-/GIM- III 
EAC19 * 44 F 1 35 1 diffuse BIM-/GIM- III 
EAC20 *  79 M 0 0 0 diffuse BIM-/GIM- IV 
EAC21 * 63 M 0 56 0 intestinal BIM-/GIM- II 
EAC22 * 84 M 0 84 0 intestinal BIM-/GIM- II 
EAC23 * 77 F 0 4 n/a* intestinal BIM-/GIM- III 
EAC24 *  78 F 1 10 1 intestinal BIM-/GIM- III 
EAC25 * 80 M 0 71 0 diffuse BIM-/GIM- I 
EAC26 *  74 M 0 19 0 intestinal BIM-/GIM- III 
EAC27 * 68 M 0 0 0 intestinal BIM-/GIM- III 
EAC28 * 72 M 0 6 0 intestinal BIM-/GIM- III 
EAC29 * 67 M 0 14 0 intestinal BIM-/GIM- II 
EAC30 * 82 M 0 14 1 intestinal BIM-/GIM- III 
EAC31 * 66 M 1 33 1 intestinal BIM-/GIM- III 
EAC32 * 54 M 1 15 0 intestinal BIM-/GIM- III 
EAC33 * 87 M 0 0 0 intestinal BIM-/GIM- II 
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EAC34 * 61 M 1 12 1 intestinal BIM-/GIM- III 
EAC35 * 82 M 1 6 1 intestinal BIM-/GIM- IV 
EAC36 * 65 M 1 29 1 intestinal BIM+/GIM- III 
EAC37 *  62 M 1 5 1 intestinal BIM+/GIM- II 
EAC38 * 54 F 0 6 0 diffuse BIM-/GIM- II 
EAC39 75 F 1 45 1 intestinal BIM-/GIM- IV 
EAC40 77 M 1 60 1 intestinal BM-/GM+ IV 
EAC41 75 M 0 16 0 intestinal BM+/GM- I 
EAC42 69 M 0 24 0 intestinal BIM-/GIM- III 
EAC43 70 F 1 48 1 diffuse BM-/GM+ III 
EAC44 66 M 1 15 1 intestinal BM-/GM- III 
EAC45 54 F 1 12 1 intestinal BIM-/GIM- IV 
EAC46 73 M 1 24 1 intestinal BM+/GM+ I 
EAC47 70 M 0 6 0 intestinal BIM-/GIM- III 
EAC48 71 M 1 4 1 intestinal BIM-/GIM- III 
EAC49 77 M 1 22 1 intestinal BM+/GM+ III 
EAC50 69 M 1 2 1 intestinal BIM-/GIM- III 
EAC51 68 M 0 0 0 intestinal BIM-/GIM- III 
EAC52 70 M 0 7 0 intestinal BM+/GM- I 
EAC53 57 M 1 6 1 intestinal BIM-/GIM- IV 
EAC54 72 M 0 7 0 intestinal BM+/GM0 III 
EAC55 80 M 0 4 0 intestinal BM-/GM+ III 
EAC56 76 M 1 n.a 1 intestinal BIM-/GIM- II 
EAC57 69 M 0 7 0 intestinal BM+/GM- IV 
EAC58 65 M 0 11 1 intestinal BIM-/GIM- IV 
EAC59 80 F 0 0 n.a diffuse BIM-/GIM- III 
EAC60 75 M 0 35 0 intestinal BM-/GM+ III 
EAC61 82 M 1 20 1 intestinal BIM-/GIM- III 
EAC62 58 F 0 15 0 intestinal BM-/GM+ II 
EAC63 72 M 0 53 0 intestinal BM-/GM+ III 
EAC64 72 M 0 29 0 intestinal BIM-/GIM- III 
EAC65 63 M 0 36 0 intestinal BM+/GM- I 
EAC66 83 M 0 18 0 intestinal BM+/GM- I 
EAC67 67 F 0 29 0 intestinal BM+/GM- I 
EAC68 66 M 0 31 0 intestinal BM+/GM- I 
EAC69 63 M 0 38 0 intestinal BM+/GM- I 
EAC70 62 M 0 58 0 intestinal BM+/GM- I 
EAC71 52 M 0 57 0 intestinal BM+/GM- I 
EAC72 60 F 0 41 0 intestinal BM+/GM- I 
EAC73 66 M 0 84 0 intestinal BM+/GM- I 
EAC74 83 F 0 6 0 intestinal BM+/GM- I 
EAC75 72 M 1 0 n.a diffuse BIM-/GIM- III 
EAC76 80 F 0 67 0 mixed BIM-/GIM- I 
EAC77 74 F 1 3 0 diffuse BIM-/GIM- II 
EAC78 71 M 1 31 1 intestinal BM+/GM- III 
EAC79 57 M 1 29 1 intestinal BM+/GM- III 
EAC80 78 M 1 11 n.a mixed BM+/GM- IV 
EAC81 70 M 0 29 0 intestinal BM+/GM- III 
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EAC82 54 M 0 30 1 intestinal BM+/GM- III 
EAC83 66 M 0 57 1 intestinal BM+/GM- III 
EAC84 68 M 0 10 0 intestinal BM+/GM- III 
EAC85 82 M 0 24 1 intestinal BM+/GM- II 
EAC86 46 M 0 25 0 intestinal BM+/GM- II 
EAC87 47 M 0 28 0 intestinal BM+/GM- III 
EAC88 60 M 0 49 0 diffuse n.a. II 
EAC89 73 M 0 62 0 intestinal n.a. IV 
EAC90 79 M 0 48 0 intestinal n.a. II 
EAC91 41 M 1 33 1 intestinal n.a. III 
EAC92 51 F 1 62 1 intestinal n.a. II 
EAC93 48 F 0 98 0 n.a n.a. III 
EAC94 62 F 1 46 1 intestinal n.a. II 
EAC95 45 F 1 16 1 intestinal n.a. III 
EAC96 61 M 1 22 1 intestinal n.a. II 
EAC97 77 M 0 102 0 intestinal n.a. II 
EAC98 13 M 0 84 0 mixed n.a. III 
EAC99 78 M 1 38 1 intestinal n.a. III 
EAC100 67 M 1 24 1 diffuse n.a. II 
EAC101 77 M 0 56 0 intestinal n.a. II 
EAC102 62 M 1 33 1 intestinal n.a. IV 
EAC103 61 M 1 24 1 intestinal n.a. IV 
EAC104 49 F 1 27 1 n.a. n.a. III 
EAC105 62 F 1 34 1 intestinal n.a. III 
EAC106 73 M 0 18 1 intestinal n.a. II 
EAC107 51 M 1 0,46 1 intestinal n.a. III 
EAC108 70 M 1 66 1 mixed n.a. III 
EAC109 62 M 1 29 1 intestinal n.a. II 
EAC110 69 F 0 29 1 intestinal n.a. III 
EAC111 44 M 0 133 0 intestinal n.a. III 
EAC112 68 F 1 40 1 intestinal n.a. III 
EAC113 76 F 0 31 0 intestinal n.a. II 
EAC114 77 M 0 16 0 intestinal n.a. II 
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Table 2: Genes represented in DEPArray™ OncoSeek Panel 
 
                       
 
 
Table 3: In the table, sequences of primers are reported 
    
Primers Sequences 
    
SMARCA4 x32 F 5’-GTAAGACCTGCTCCTCCCG-3’ 
SMARCA4 x32 R 5’-ATTCAGAAGGGAAGGAGGGG-3’ 
TP53 x8 F 5’-CTTTTCCTATCCTGAGTAGTGGT-3’ 
TP53 x8 R 5’-TGTCCTGCTTGCTTACCTCG-3’ 
TP53 x6 F 5’-CCTCCTCAGCATCTTATCCGA-3’ 
TP53 x6 R 5’-TTGCAAACCAGACCTCAGG-3’ 
M13 F 5’-GTAAAACGACGGCCAG-3’ 
M13 R 5’-CAGGAAACAGCTATGAC-3’ 
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Table 4: Clinical and epidemiological information for EAC cases included in the 
study: fresh-frozen cohort.  
n.a.= not available 
 











T130 1 8 n.a. no intestinal 
T131 1 21 1 yes mixed 
T133 1 28 1 no intestinal 
T136 0 30 0 no diffuse 
T137 0 33 0 no intestinal 
T138 1 12 n.a. no mixed 
T139 1 2 n.a. no diffuse 
T140 1 10, 1 no diffuse 
T141 1 21 n.a. no intestinal 
T119 0 37 0 yes intestinal 
T120 0 5 0 no diffuse 
T121 1 20 n.a. no intestinal 
T122 0 39 0 no intestinal 
T123 1 17 n.a. no intestinal 
T124 1 8 1 yes mixed 
T125 0 36 0 yes intestinal 
T142 0 31 1 no intestinal 
T145 0 10 0 no intestinal 
T146 0 30 1 no intestinal 
T147 0 32 1 no intestinal 
T134 1 9 n.a. no intestinal 
T150 1 8 n.a. no diffuse 
T159 0 20 0 no intestinal 
T161 0 22 0 no intestinal 
T162 0 15 n.a. no intestinal 
T5 1 16 1 yes mixed 
T7 1 15 1 yes intestinal 
T8 1 14 n.a. no diffuse 
T9 1 17 1 yes intestinal 
T11 1 38 1 no intestinal 
T12 0 72 0 yes mixed 
T15 0 72 0 yes intestinal 
T16 1 32 1 no intestinal 
T17 1 40 1 yes diffuse 
T19 0 82 0 yes intestinal 
T27 0 70 0 yes intestinal 
T29 0 70 0 no mixed 
T30 0 21 0 yes n.a. 
T31 1 7 n.a. no intestinal 
T34 1 20 1 yes intestinal 
T173 0 21 0 no intestinal 
T175 0 20 0 yes mixed 
T32 0 71 0 yes diffuse 
T43 1 19 n.a. no intestinal 
T23 0 71 1 yes intestinal 
T24 0 5 0 yes intestinal 
T126 0 29 0 no intestinal 
T128 1 12 1 yes intestinal 
T112 0 44 0 no intestinal 
T115  1 14 1 yes intestinal 
T156 0 27 0 no mixed 
T116 0 38 0 no intestinal 
T158 0 22 0 yes diffuse 
T160 0 25 0 yes intestinal 
T163 0 24 0 no diffuse 
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T166 0 21 0 yes intestinal 
T167 0 12 n.a. no intestinal 
T169 0 22 1 no mixed 
T45 1 42 1 yes diffuse 
T155 1 15 n.a. no intestinal 
T170 0 18 0 yes intestinal 
 
 
Table 5: Summary statistics regarding DEPArray™ recoveries and OncoSeek 
sequencing. DNA index is a measure of DNA content, determined comparing the 
integral-intensity DAPI of tumor population with that of stromal fraction, used as 
reference. All tumor populations show a hyperdiploid profile, compared to the expected 
diploid stromal profile. EAT (Effective Addressable Template) is a number estimating 
the usable template for DEPArray™ OncoSeek assay and can be considered a measure 
of sample quality. It is determined according to the following formula: n.cells x 
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Table 6: EXCAVATOR2 output for CNV on chromosome 6 and 17. 
EXCAVATOR2 results reports chromosome [CHROM], start [START], end [END] 
(positions compared to the reference genomic sequence hg19), segment length of a 
specific copy number [SEGMENT], copy number value (rounded to nearest integer) 
[CN], call probability inferred by FastCall algorithm [ProbCall], for EAC primary 











 CHROM START END SEGMENT CN ProbCall 
EAC 
(PT) 
6 109294558 109761795 467 kb 4 0.933 
6 123573555 123905087 331 kb 3 0.895 
17 37263657 38948823 1,7 Mb 17 0.999 
M1 
6 109308744 109761795 453 kb 4 0.945 
6 123573555 123905087 331 kb 4 0.780 
17 37295904 38948823 1,7 Mb 11 0.988 
M2 
6 108843497 109761795 918 kb 3 0.933 
6 123545236 123868517 323 kb 3 0.891 
6 127601482 127636156 34 kb 39 0.999 
17 37263657 38948823 1,7 Mb 11 0.999 
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Table 7: Somatic mutations and CNA detected with the OncoSeek panel analysis of sorted cell populations. Mutations detected in 
sorted pure populations of EAC; red: hyperdiploid tumor cells; blue: pseudodiploid tumor cells. The value reported in each cell in the table 
represents the alternative allele frequency of the detected variants; yellow: missense mutations; green: loss-of-function mutations (indel and 
nonsense); violet: CNAs. On the right column, we reported the number of mutations and copy number amplifications per sample. On the 
left column, we reported the sample ID. Only cases with variants identified in the 63 genes present in the OncoSeek panel are shown. 
 
1 2 3 4 5 6 7







99,75 63,13 0,00 99,88
41,44 30,68 62,50 39,02 45,88 31,75 41,48 28,84 53,39 46,01
96,75 98,21 33,62 31,99
79,87 95,99 88,99 75,15 50,81 60,49
0,00 45,67
44,10 17,05 3,97 53,83 77,08 63,40 56,92 53,19 30,32 0,00 35,53 18,28
100,00 100,00
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CTNNB1 APC ERBB2 CDK6 MYC METKRAS SRC RET MAP2K1 NRAS MSH6ATM PTEN STK11 EGFR FLT3 IDH2TP53 SMAD4 CDKN2A PIK3CA HNF1A
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Table 8: p53 immunohistochemistry and TP53 mutation status.  
We report in black the missense mutation; in red stop codon (*) and frameshift (fs) 
mutations. wt=wild-type. TA classes and GVGD scores, according to IARC TP53 
Database (http://p53.iarc.fr/) are based: a) for TA classes, on the overall transcriptional 
activity (TA) on 8 different promoters as measured in yeast assays [110]. For each 
mutation, the median of the 8 promoter-specific activities (expressed as percent of the 
wild-type protein) is calculated and missense mutations are classified as "non-
functional" if the median is <=20, "partially functional" if the median is >20 and <=75, 
"functional" if the median is >75 and <=140, and "supertrans" if the median is >140; b) 
for the GVGD scores, classification is based on alignments obtained with Align-GVGD 
tool for TP53 missense variant prediction [159]. C15 is considered the best cut-off of 
pathogenicity.  
 
EAC_ID p53 immunostaining TP53 mutation TA classa  GVGD 
classb 
EAC1 overexpression p.R282W non-functional C65 
EAC2 no overexpression wt - - 
EAC3 overexpression p.C176F partially functional  C65 
EAC4 no overexpression p.P75L non-functional C0 
EAC5 no overexpression p.P191Sfs*18 - - 
EAC6 no overexpression p.R273H non-functional C25 
EAC7 no overexpression 













EAC9 overexpression p.R273C non-functional C65 
EAC10 no overexpression p.S303Afs*42 - - 
EAC11 overexpression p.R273H non-functional C25 
EAC12 overexpression p.R273C non-functional C65 
EAC13 no overexpression wt - - 
EAC14 no overexpression wt - - 
EAC15 no overexpression p.R248Q non-functional C35 
EAC16 overexpression p.C275F non-functional C65 
EAC17 overexpression p.R175H non-functional C25 
EAC18 no overexpression p.R342* - - 
EAC19 no overexpression wt - - 
EAC20 overexpression p.P278S non-functional C65 
EAC21 overexpression p.R273C non-functional C65 
EAC22 overexpression p.R175H non-functional C25 
EAC23 no overexpression wt - - 
EAC24 no overexpression wt - - 
EAC25 overexpression p.R175H non-functional C25 
EAC26 overexpression p.R273H non-functional C25 
EAC27 overexpression p.R196* - - 
EAC28 no overexpression p.S15Rfs*28 - - 
EAC29 no overexpression p.L43V functional C0 
EAC30 overexpression p.D259V non-functional C15 
EAC31 overexpression p.R248W non-functional C65 
EAC32 overexpression p.R267G non-functional C65 
EAC33 no overexpression p.Q167* - - 
EAC34 no overexpression wt - - 
EAC35 no overexpression wt - - 
EAC36 overexpression p.Y220C non-functional C65 
EAC37 no overexpression wt - - 
EAC38 overexpression wt - - 
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Table 9: Fisher’s test output for p53 immunostaining and the presence of missense 
mutations. 
 
 Missense change 
present  
Others 
(no mutation / loss-
of-function) 
Total 
p53 overexpression 17 2 19 
p53 no overexpression 5 14 19 
Total  22 16 38 
 P = 0.0002 
 
 
Table 10: Crosstab showing the relationship between TP53 mutational status and 
Lauren’s classification. The chi-squared test for given probabilities and Bonferroni's 
correction were applied to calculate the P-values (P) showed in table.  
 
 TP53 Total P 
Lauren wt mutant  
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Table 11: Multivariate forward stepwise analysis of clinical and mutational 
parameters associated with survival. In table, we only reported the potential 
predictive parameters. The TP53 mutations, the Lauren intestinal subtype and the 
cancers with intestinal metaplasia in esophagus (BIM+/GIM-) or in stomach (BIM-
/GIM+), who showed a significant negative coefficient (b), are significantly correlated 
with better survival.  
 




-3.146 0.000 0.043 0.007 0.249 
BIM/GIM       
 BIM+/GIM- -3.522 0.001 0.030 0.004 0.241 
 BIM-/GIM+ -3.451 0.001 0.032 0.004 0.262 
Lauren Intestinal -3.035 0.005 0.048 0.006 0.405 
 
 
Table 12: SMAD4 immunoreactivity and genetic status of SMAD4 and 
TP53/CDKN2A (TP53-pathway) genes. 
 
EAC_ID SMAD4 loss 
(%) 
SMAD4 mutations TP53-pathway mutations 
(1=yes) 
EAC7 0 - 1 
EAC6 0 - 1 
EAC15 0 - 1 
EAC26 0 - 1 
EAC18 0 - 1 
EAC14 0 - 0 
EAC5 0 - 1 
EAC20 0 - 1 
EAC11 0 - 1 
EAC33 0 - 1 
EAC29 0 - 1 
EAC34 10 - 0 
EAC13 10 - 0 
EAC3 15 - 1 
EAC2 20 - 0 
EAC25 20 - 1 
EAC31 30 - 1 
EAC9 40 - 1 
EAC24 40 - 0 
EAC32 50 - 1 
EAC30 50 - 1 
EAC23 50 p.R361C 0 
EAC10 50 - 1 
EAC4 60 - 1 
EAC19 80 - 0 
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EAC21 80 - 1 
EAC38 90 - 0 
EAC12 90 p.S144* 1 
EAC36 90 - 1 
EAC22 90 - 1 
EAC1 99 - 1 
EAC16 100 - 1 
EAC17 100 p.G176* 1 
EAC35 100 - 1 
 
 
Table 13: List of deregulated miRNAs determined by TaqMan MicroRNA Array 
cards in 8 EAC cases compared to two pools of 8 controls. Down-regulated miRNAs 
are highlighted in gray and up-regulated in orange.  
 
Target name Relative Quantity Adjusted P-value 
hsa-miR-1293-002905 316.564 0.015 
hsa-miR-518b-001156 18.437 0.004 
hsa-miR-483-3p-002339 11.033 0.050 
hsa-miR-125b-000449 5.632 0.050 
hsa-miR-708-002341 5.266 0.031 
hsa-miR-604-001567 4.799  0.014 
hsa-miR-146b-3p-002361 4.773  0.041 
hsa-miR-214-002306 4.262 0.043 
hsa-miR-1290-002863 3.693 0.028 
hsa-miR-199a-3p-002304 2.885 0.024 
hsa-miR-502-001109 2.815 0.018 
hsa-miR-181c-000482 2.796 0.017 
hsa-miR-221-000524 2.746 0.050 
hsa-miR-330-000544 2.571 0.041 
hsa-miR-331-000545 2.476 0.041 
hsa-miR-671-3p-002322 2.398 0.028 
hsa-miR-100-000437 2.334 0.050 
hsa-miR-935-002178 2.213 0.041 
hsa-miR-197-000497 2.091 0.050 
hsa-miR-214#-002293 2.062 0.050 
hsa-miR-337-5p-002156 2.026 0.028 
hsa-let-7a-000377 1.983 0.038 
hsa-miR-636-002088 1.981 0.050 
hsa-miR-501-001047 1.960 0.047 
hsa-miR-493-002364 1.573 0.039 
hsa-miR-324-3p-002161 1.492 0.031 
hsa-miR-484-001821 0.702 0.009 
hsa-miR-30c-000419 0.620 0.010 
hsa-miR-30b-000602 0.595 0.004 
hsa-miR-376c-002122 0.557 0.001 
hsa-miR-543-002376 0.538 0.024 
hsa-miR-136#-002100 0.531 0.028 
hsa-miR-186-002285 0.529 0.026 
hsa-miR-148b#-002160 0.499 0.049 
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hsa-miR-342-5p-002147 0.492 0.003 
hsa-miR-126#-000451 0.486 0.022 
hsa-miR-33a#-002136 0.474 0.005 
hsa-miR-26b-000407 0.469 0.001 
hsa-miR-628-3p-002434 0.444 0.025 
hsa-miR-10b#-002315 0.443 0.002 
hsa-miR-29b-2#-002166 0.434 0.011 
hsa-miR-942-002187 0.432 0.006 
hsa-miR-590-3P-002677 0.424 0.040 
hsa-miR-625-002431 0.422 0.011 
hsa-let-7g-002282 0.412 0.000 
hsa-miR-575-001617 0.402 0.025 
hsa-let-7g#-002118 0.401 0.001 
hsa-miR-505-002089 0.400 0.026 
hsa-miR-628-5p-002433 0.385 0.001 
hsa-miR-140-3p-002234 0.383 0.007 
hsa-miR-146a-000468 0.347 0.041 
hsa-miR-139-5p-002289 0.347 0.041 
hsa-miR-411-001610 0.340 0.000 
hsa-miR-199b-000500 0.339 0.001 
hsa-miR-26a-1#-002443 0.332 0.003 
hsa-miR-148a-000470 0.328 0.015 
hsa-miR-598-001988 0.315 0.000 
hsa-miR-136-000592 0.312 0.021 
hsa-miR-888-002212 0.300 0.033 
hsa-miR-30e-3p-000422 0.288 0.005 
hsa-miR-30a-5p-000417 0.284 0.002 
hsa-miR-15b#-002173 0.273 0.041 
hsa-let-7a#-002307 0.258 0.003 
hsa-miR-378-002243 0.257 0.038 
hsa-miR-486-3p-002093 0.245 0.000 
hsa-miR-200a-000502 0.244 0.026 
hsa-miR-30a-3p-000416 0.235 0.001 
hsa-miR-130b#-002114 0.234 0.012 
hsa-miR-190b-002263 0.231 0.001 
hsa-miR-192-000491 0.225 0.031 
hsa-miR-148a#-002134 0.219 0.002 
hsa-miR-411#-002238 0.216 0.002 
hsa-miR-625#-002432 0.197 0.000 
hsa-miR-326-000542 0.181 0.004 
hsa-miR-485-5p-001036 0.180 0.009 
hsa-miR-200a#-001011 0.178 0.013 
hsa-miR-486-001278 0.173 0.047 
hsa-miR-363-001271 0.173 0.003 
hsa-miR-642-001592 0.167 0.000 
hsa-miR-375-000564 0.167 0.025 
hsa-miR-1262-002852 0.152 0.000 
hsa-miR-376a#-002127 0.142 0.031 
hsa-miR-144-002676 0.131 0.001 
hsa-miR-520c-3p-002400 0.128 0.031 
hsa-miR-30c-2#-002110 0.121 0.011 
hsa-miR-135a-000460 0.121 0.002 
hsa-miR-204-000508 0.120 0.001 
hsa-miR-31-002279 0.078 0.011 
hsa-miR-7-2#-002314 0.071 0.000 
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hsa-miR-1179-002776 0.065 0.003 
hsa-miR-518d-5p-002389 0.064 0.008 
hsa-miR-567-001534 0.063 0.026 
hsa-miR-144#-002148 0.043 0.000 
hsa-miR-672-002327 0.033 0.000 
hsa-miR-595-001987 0.000 0.000 
hsa-miR-520h-001170 0.000 0.000 
hsa-miR-346-000553 0.000 0.000 
hsa-miR-208b-002290 0.000 0.002 
 
 
Table 14: SMAD4 immunoreactivity and miR-483-3p expression levels. Fold 
change was calculated using 2-ΔΔCT method, comparing FFPE tumor cases versus the 
pool of 8 control tissues. Up-regulated miRNA (cut-off value 3.15) and SMAD4 protein 
loss (cut-off value 30% of cancer cells) are highlighted in red; down-regulated miRNA 
and high SMAD4 expression are highlighted in green.  
n.a.= not available 
 
ID % of SMAD4 LOSS miR-483-3p fold-change 
EAC7 0 2,5 
EAC6 0 2,99 
EAC15 0 1,51 
EAC46 0 2,48 
EAC42 0 53,53 
EAC41 0 18,22 
EAC26 0 6,54 
EAC18 0 3,31 
EAC47 0 18,23 
EAC14 0 3,85 
EAC5 0 n.a. 
EAC20 0 0,72 
EAC11 0 0,77 
EAC33 0 3,45 
EAC64 0 15,56 
EAC29 0 3,74 
EAC34 10 2,18 
EAC43 10 6,89 
EAC13 10 1,59 
EAC60 10 24,7 
EAC61 10 5.03 
EAC59 10 7,33 
EAC76 10 19,61 
EAC3 15 6,69 
EAC40 20 5,1 
EAC2 20 n.a. 
EAC25 20 2,79 
EAC31 30 2,19 
EAC45 40 18,05 
EAC9 40 0,87 
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EAC24 40 37,49 
EAC39 45 3,43 
EAC32 50 14 
EAC30 50 0,33 
EAC23 50 5,61 
EAC10 50 16,12 
EAC4 60 0,12 
EAC63 60 3,14 
EAC77 60 42,25 
EAC19 80 1,48 
EAC75 80 15,69 
EAC21 80 11,53 
EAC44 90 3,55 
EAC38 90 10,76 
EAC12 90 1,91 
EAC36 90 11,95 
EAC62 90 11,78 
EAC22 90 1,66 
EAC48 95 12,28 
EAC50 95 6,2 
EAC1 99 16,45 
EAC16 100 1,02 
EAC17 100 1,4 
EAC49 100 27,36 
EAC35 100 11,75 
 
 
Table 15: PTEN immunoreactivity and miR-221 expression levels. Fold change was 
calculated using 2-ΔΔCT method, comparing FFPE tumor cases versus the pool of 8 
control tissues. Up-regulated miRNA (cut-off value 1.32) and PTEN protein loss (cut-
off value 50% of cancer cells) are highlighted in red; down-regulated miRNA and 
normal PTEN expression are highlighted in green.  
 
ID PTEN expression miR-221 fold-change 
EAC16 LOSS 0,19 
EAC40 LOSS 0,38 
EAC15 LOSS 0,46 
EAC30 LOSS 0,49 
EAC54 LOSS 0,5 
EAC33 LOSS 0,52 
EAC12 LOSS 0,56 
EAC29 NORMAL 0,58 
EAC3 LOSS 0,61 
EAC52 NORMAL 0,69 
EAC31 LOSS 0,79 
EAC1 NORMAL 0,82 
EAC34 LOSS 0,84 
EAC64 LOSS 0,88 
EAC38 LOSS 0,9 
EAC51 NORMAL 1 
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EAC60 LOSS 1,14 
EAC9 LOSS 1,17 
EAC28 LOSS 1,29 
EAC4 LOSS 1,4 
EAC32 NORMAL 1,48 
EAC11 LOSS 1,58 
EAC46 LOSS 1,64 
EAC13 LOSS 1,69 
EAC44 LOSS 2,08 
EAC43 LOSS 2,09 
AC59 NORMAL 2,09 
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